adenine has been researched along with Lymphoma, Mantle-Cell in 208 studies
Lymphoma, Mantle-Cell: A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).
Excerpt | Relevance | Reference |
---|---|---|
" Two weeks after the regular dose was restarted (month 3), the patient had repeated bleeding (patient was receiving aspirin for previous MI) and had to stop ibrutinib again." | 4.93 | Walking a tightrope: clinical use of ibrutinib in mantle cell lymphoma in the elderly. ( Ruella, M; Soubeyran, P, 2016) |
" Ibrutinib use, age, hypertension, and previous use of ACE inhibitors, angiotensin receptor blocker use, β blocker use, and aspirin use were independently associated with incident arrhythmias." | 3.91 | Rates and Risk of Atrial Arrhythmias in Patients Treated With Ibrutinib Compared With Cytotoxic Chemotherapy. ( Armanious, M; Chavez, JC; Emole, J; Fradley, MG; Gliksman, M; Lee, DH; McLeod, H; Pinilla-Ibarz, J; Rhea, I; Schabath, MB; Shah, B; Viganego, F; Walko, C; Welter-Frost, A, 2019) |
" The clinical behavior of MCL may be due to the complex pathophysiology of the disease which includes its genetic hallmark, the chromosomal translocation t(11;14) resulting in aberrant expression of cyclin D1, alteration in the DNA damage response, and constitutive activation of key anti-apoptotic pathways such as phosphatidyl-inositol 3-kinase (PI3K)/Akt and nuclear factor-kB (NF-kB)." | 3.78 | Novel targeted therapies for mantle cell lymphoma. ( Alinari, L; Baiocchi, RA; Christian, B, 2012) |
" The most common grade 3 adverse events were rash/pruritis/dermatitis (19%), diarrhea (11%), hyperglycemia (11%), and hypertension (11%)." | 3.11 | Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring. ( Batlevi, CL; De Frank, S; Drullinsky, P; Gerecitano, JF; Hamilton, A; Hamlin, PA; Horwitz, SM; Kumar, A; Matasar, MJ; Michaud, L; Moskowitz, A; Moskowitz, CH; Nakajima, R; Nichols, C; Rademaker, J; Salles, G; Schöder, H; Seshan, V; Stewart, CM; Straus, D; Tsui, DWY; Whiting, K; Younes, A; Zelenetz, AD, 2022) |
" We sought to identify the optimal dosing combination, based on efficacy and toxicity, utilizing a continual reassessment method of 6 combinations of IBR (280 mg, 420 mg, and 560 mg by mouth daily) and VEN (max dose of 200 mg and 400 mg by mouth daily)." | 3.11 | Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma. ( Budde, LE; Chen, RW; Cohen, JB; Kahl, BS; Petroni, GR; Portell, CA; Varhegyi, NE; Wages, NA; Williams, ME, 2022) |
" We hypothesized that a tailored treatment with ibrutinib in combination with rituximab (IR) could obtain significant responses in these patients." | 3.11 | Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial. ( Aymerich, M; Beà, S; Campo, E; Casanova, M; Cortés-Romera, M; de la Cruz, F; de la Fuente, A; García Sanz, R; Giné, E; González Barca, E; González-López, TJ; Jiménez Ubieto, A; López Jimenez, J; López-Guillermo, A; Marín-Niebla, A; Martín García-Sancho, A; Medina Herrera, A; Muntañola, A; Nadeu, F; Rodríguez, S; Rotger, A; Setoain, X; Terol, MJ, 2022) |
" The recommended phase 2 dose of umbralisib when given in combination with ibrutinib was 800 mg once daily." | 2.90 | Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study. ( Arnason, JE; Bazemore, J; Boruchov, AM; Brown, JR; Davids, MS; Fisher, DC; Francoeur, K; Hellman, JM; Jacobsen, ED; Jacobson, CA; Kim, HT; Maegawa, R; Miskin, HP; Nicotra, A; Rueter, J; Savell, A; Sportelli, P; Stampleman, L, 2019) |
"We conducted an integrated safety analysis to characterize the frequency, severity, natural history, and outcomes of adverse events (AEs) with ibrutinib versus comparators." | 2.87 | Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma. ( Barr, PM; Burger, JA; Chang, S; Coutre, S; Cramer, P; Dilhuydy, MS; Fraser, G; Graef, T; Hess, G; Hillmen, P; Howes, A; James, DF; Liu, E; Moreno, C; O'Brien, S; Patel, K; Styles, L; Tedeschi, A; Valentino, R; Vermeulen, J, 2018) |
"Lenalidomide is an immunomodulatory agent that has demonstrated clinical benefit for patients with relapsed or refractory mantle cell lymphoma (MCL); however, despite this observed clinical activity, the mechanism of action (MOA) of lenalidomide has not been characterized in this setting." | 2.84 | Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity. ( Apollonio, B; Chiu, H; Chopra, R; Couto, S; Flynt, E; Gandhi, AK; Hagner, PR; Ortiz, M; Ramsay, AG; Thakurta, A; Trotter, M; Waldman, MF; Wang, M, 2017) |
"Ibrutinib combined with rituximab is active and well tolerated in patients with relapsed or refractory mantle cell lymphoma." | 2.82 | Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. ( Addison, A; Badillo, M; Champlin, R; Chen, W; Chuang, H; DeLa Rosa, M; Fayad, L; Hagemeister, F; Lam, L; Lee, H; Li, S; Medeiros, LJ; Nomie, K; Oki, Y; Romaguera, J; Samaniego, F; Santos, D; Turturro, F; Wagner-Bartak, N; Wang, ML; Westin, J; Young, KH; Zhang, H; Zhang, L; Zhao, D, 2016) |
" A total of 8/16 patients (50%) had at least one grade 3 adverse event (AE), and 5 (31." | 2.82 | Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma. ( Choi, I; Fukuhara, N; Hatake, K; Ishikawa, T; Kinoshita, T; Kitano, T; Maruyama, D; Matsuno, Y; Nagai, H; Nishikawa, T; Nishikori, M; Shibayama, H; Takahara, S; Tobinai, K; Uchida, T, 2016) |
" We developed a population pharmacokinetic (PK) model for ibrutinib in patients." | 2.80 | Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies. ( Advani, R; Byrd, JC; de Jong, J; De Nicolao, G; de Trixhe, XW; Loury, D; Marostica, E; McGreivy, J; O'Brien, S; Poggesi, I; Sukbuntherng, J; Vermeulen, A, 2015) |
" Outcomes assessed included overall response rate (ORR), complete response (CR) rate, overall survival (OS), progression-free survival (PFS), and adverse events." | 2.61 | Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma. ( Abhyankar, S; Kabadi, SM; Signorovitch, J; Song, J; Telford, C; Yao, Z; Zhao, J, 2019) |
" Although generally well tolerated, here we describe our institutional experience of unique adverse effects encountered with the use of ibrutinib in patients with B-cell lymphomas." | 2.61 | Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies-A single institution experience and a review of literature. ( Albrethsen, M; Chilkulwar, A; Faisal, MS; Fazal, S; Khattab, A; Sadashiv, S; Shaikh, H, 2019) |
"Discussion One patient with chronic lymphocytic leukemia/small lymphocytic lymphoma and one patient with mantle cell lymphoma developed laboratory and clinical tumor lysis syndrome following initiation of ibrutinib therapy." | 2.58 | Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: A case series and review of the literature. ( Brown, JN; Hammond, JM; Titus-Rains, KS, 2018) |
" In a recently published phase 3 trial (RESONATE) that compared ibrutinib and ofatumumab for the treatment of relapsed and refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, ibrutinib at the daily dosage of 420 mg demonstrated a significantly higher overall response rate (43% in ibrutinib vs." | 2.53 | A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib. ( Kim, SS; Lee, CS; Rattu, MA, 2016) |
"Limited published real-world data describe adverse events (AEs) among patients treated for mantle-cell lymphoma (MCL)." | 1.62 | Adverse Events and Economic Burden Among Patients Receiving Systemic Treatment for Mantle Cell Lymphoma: A Real-World Retrospective Cohort Study. ( Byfield, SD; Kabadi, SM; LE, L; Olufade, T, 2021) |
"Ibrutinib is an established treatment for relapsed/refractory (R/R) mantle cell lymphoma (MCL) and clinical trial data supports use at second line compared to later relapse." | 1.62 | Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients. ( Arasaretnam, A; Bishton, M; Bolam, S; Creasey, T; Crosbie, N; Dawi, S; Dutton, D; Eyre, TA; Follows, G; Goradia, H; Harrison, S; Johnston, R; Kirkwood, AA; Lambert, J; Lewis, D; McCulloch, R; McKay, P; McMillan, A; Miles, O; Osborne, W; Patmore, R; Phillips, N; Robinson, A; Rule, S; Wilson, MR, 2021) |
"In severe enterovirus infections, we recommend subtyping for the development of efficient preventive and therapeutic strategies." | 1.56 | Life-threatening disseminated enterovirus infection during combined rituximab and ibrutinib maintenance treatment for mantle cell lymphoma: a case report. ( Cana, D; Hess, G; Higer, M; Podlech, J; Schadmand-Fischer, S; Schwarting, A; Teschner, D; Theobald, M; Wölfel, T, 2020) |
"There are limited data on treatment patterns, adverse events (AEs), and economic burden in younger, commercially insured patients treated for mantle cell lymphoma (MCL)." | 1.51 | Treatment patterns, adverse events, healthcare resource use and costs among commercially insured patients with mantle cell lymphoma in the United States. ( Burudpakdee, C; Kabadi, SM; Near, A; Wada, K, 2019) |
"Invasive bacterial infections developed in 23 (53." | 1.48 | Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer. ( Cohen, N; Hohl, TM; Palomba, ML; Redelman-Sidi, G; Seo, SK; Taur, Y; Varughese, T, 2018) |
" The additive and synergistic inhibition of this combination additionally supports a therapeutic strategy involving lower dosing of each drug to reduce potential side effects." | 1.48 | Additive and synergistic inhibition of mantle cell lymphoma cell growth by combining olaparib with ibrutinib. ( Curtis, A; Rajan, S; Rueter, J; Shopland, L; Zhang, R, 2018) |
"Lenalidomide-based treatment showed clinical activity, with no unexpected toxicities, in patients with relapsed/refractory mantle cell lymphoma who previously failed ibrutinib therapy." | 1.46 | Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004). ( Barnett, E; Bravo, MC; Ghosh, N; Goy, A; Hamadani, M; Lossos, IS; Martin, P; Phillips, T; Reeder, CB; Rule, S; Schuster, SJ; Wang, M, 2017) |
"Lercanidipine 10 mg daily was prescribed as an alternative antihypertensive drug." | 1.43 | Adverse event potentially due to an interaction between ibrutinib and verapamil: a case report. ( Bilbault, P; Gourieux, B; Lambert Kuhn, E; Levêque, D; Lioure, B, 2016) |
"Among 31 patients who experienced disease progression following ibrutinib and underwent salvage therapy, the overall and complete response rates were 32% and 19%, respectively." | 1.42 | Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. ( Champlin, RE; Cheah, CY; Chihara, D; Fowler, NH; Hagemeister, FB; Romaguera, JE; Seymour, JF; Wang, ML, 2015) |
" We investigated the efficacy of the histone deacetylase (HDAC) inhibitor vorinostat combined with one of several B-cell receptor (BCR) signaling inhibitors on MCL cell death and the underlying mechanisms, using MCL cell lines." | 1.42 | The synergistic effect of BCR signaling inhibitors combined with an HDAC inhibitor on cell death in a mantle cell lymphoma cell line. ( Hagiwara, K; Iida, H; Kunishima, S; Miyata, Y; Nagai, H; Naoe, T, 2015) |
" We here compare bortezomib with carfilzomib and LU-102 in MM and MCL in vitro with regard to their effects on pIκB/NF-κB signaling and their cytotoxic activity in combination with ibrutinib." | 1.42 | The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells. ( Bader, J; Besse, L; de Bruin, G; Driessen, C; Geurink, PP; Kisselev, AF; Kraus, J; Kraus, M; Liu, N; Overkleeft, H, 2015) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 152 (73.08) | 24.3611 |
2020's | 56 (26.92) | 2.80 |
Authors | Studies |
---|---|
Yuan, J | 1 |
Zhang, Q | 9 |
Wu, S | 2 |
Yan, S | 1 |
Zhao, R | 2 |
Sun, Y | 7 |
Tian, X | 2 |
Zhou, K | 1 |
Stewart, CM | 1 |
Michaud, L | 1 |
Whiting, K | 2 |
Nakajima, R | 1 |
Nichols, C | 2 |
De Frank, S | 1 |
Hamlin, PA | 2 |
Matasar, MJ | 1 |
Gerecitano, JF | 1 |
Drullinsky, P | 1 |
Hamilton, A | 1 |
Straus, D | 1 |
Horwitz, SM | 1 |
Kumar, A | 2 |
Moskowitz, CH | 1 |
Moskowitz, A | 1 |
Zelenetz, AD | 2 |
Rademaker, J | 1 |
Salles, G | 2 |
Seshan, V | 2 |
Schöder, H | 1 |
Younes, A | 2 |
Tsui, DWY | 1 |
Batlevi, CL | 1 |
Portell, CA | 3 |
Wages, NA | 2 |
Kahl, BS | 3 |
Budde, LE | 1 |
Chen, RW | 2 |
Cohen, JB | 2 |
Varhegyi, NE | 1 |
Petroni, GR | 2 |
Williams, ME | 4 |
Wang, M | 20 |
Ramchandren, R | 1 |
Chen, R | 1 |
Karlin, L | 1 |
Chong, G | 1 |
Jurczak, W | 11 |
Wu, KL | 1 |
Bishton, M | 2 |
Collins, GP | 1 |
Eliadis, P | 1 |
Peyrade, F | 1 |
Lee, Y | 1 |
Eckert, K | 1 |
Neuenburg, JK | 1 |
Tam, CS | 8 |
Jain, P | 4 |
Zhao, S | 3 |
Lee, HJ | 7 |
Hill, HA | 2 |
Ok, CY | 4 |
Kanagal-Shamanna, R | 4 |
Hagemeister, FB | 4 |
Fowler, N | 4 |
Fayad, L | 5 |
Yao, Y | 7 |
Liu, Y | 13 |
Moghrabi, OB | 1 |
Navsaria, L | 2 |
Feng, L | 2 |
Nogueras Gonzalez, GM | 2 |
Xu, G | 3 |
Thirumurthi, S | 3 |
Santos, D | 4 |
Iliescu, C | 1 |
Tang, G | 2 |
Medeiros, LJ | 4 |
Vega, F | 2 |
Avellaneda, M | 1 |
Badillo, M | 9 |
Flowers, CR | 2 |
Wang, L | 8 |
Wang, ML | 14 |
Giné, E | 2 |
de la Cruz, F | 1 |
Jiménez Ubieto, A | 1 |
López Jimenez, J | 1 |
Martín García-Sancho, A | 2 |
Terol, MJ | 1 |
González Barca, E | 1 |
Casanova, M | 1 |
de la Fuente, A | 1 |
Marín-Niebla, A | 2 |
Muntañola, A | 1 |
González-López, TJ | 1 |
Aymerich, M | 1 |
Setoain, X | 1 |
Cortés-Romera, M | 1 |
Rotger, A | 1 |
Rodríguez, S | 1 |
Medina Herrera, A | 1 |
García Sanz, R | 1 |
Nadeu, F | 2 |
Beà, S | 2 |
Campo, E | 2 |
López-Guillermo, A | 2 |
Nastoupil, L | 2 |
Westin, JR | 1 |
Samaniego, F | 3 |
Steiner, R | 1 |
Nair, R | 1 |
Iyer, SP | 1 |
Xuelin, H | 1 |
Wagner-Bartak, N | 2 |
Lin, P | 1 |
Wang, SA | 1 |
Jorgensen, J | 1 |
Yin, CC | 1 |
Li, S | 6 |
Patel, KP | 1 |
Mu, J | 2 |
Liu, M | 4 |
Wang, J | 11 |
Meng, J | 1 |
Zhang, R | 2 |
Jiang, Y | 2 |
Deng, Q | 2 |
Qualls, D | 1 |
Lam, HY | 1 |
Matasar, M | 1 |
Owens, C | 1 |
Espeleta, JA | 1 |
Qiu, A | 1 |
Subzwari, S | 1 |
Biggar, E | 1 |
Batlevi, C | 1 |
Siddiqi, T | 1 |
Coutre, S | 2 |
McKinney, M | 1 |
Barr, PM | 3 |
Rogers, K | 1 |
Mokatrin, A | 1 |
Valentino, R | 2 |
Szoke, A | 1 |
Deshpande, S | 4 |
Zhu, A | 1 |
Arango-Hisijara, I | 1 |
Osei-Bonsu, K | 1 |
O'Brien, S | 3 |
Zinzani, PL | 2 |
Martelli, M | 1 |
Ferrero, S | 2 |
Gentile, M | 2 |
Laurenti, L | 1 |
Romana Mauro, F | 1 |
Sportoletti, P | 1 |
Tedeschi, A | 2 |
Varettoni, M | 1 |
Visco, C | 1 |
Ye, H | 2 |
Huang, S | 6 |
Chen, Z | 6 |
Jiang, VC | 1 |
Sancho, JM | 1 |
Fernández, S | 1 |
Capote, FJ | 1 |
Cañigral, C | 1 |
Grande, C | 1 |
Donato, E | 1 |
Zeberio, I | 1 |
Puerta, JM | 1 |
Rivas, A | 1 |
Pérez-Ceballos, E | 1 |
Vale, A | 1 |
Salar, A | 1 |
González-Barca, E | 1 |
Teruel, A | 1 |
Pastoriza, C | 1 |
Conde-Royo, D | 1 |
Sánchez-García, J | 1 |
Barrenetxea, C | 1 |
Arranz, R | 1 |
Hernández-Rivas, JÁ | 3 |
Ramírez, MJ | 1 |
Jiménez, A | 2 |
Rubio-Azpeitia, E | 1 |
Jerkeman, M | 7 |
Trotman, J | 1 |
Belada, D | 1 |
Boccomini, C | 1 |
Flinn, IW | 1 |
Giri, P | 1 |
Goy, A | 6 |
Hermine, O | 1 |
Hong, X | 1 |
Kim, SJ | 3 |
Lewis, D | 2 |
Mishima, Y | 1 |
Özcan, M | 1 |
Perini, GF | 1 |
Pocock, C | 1 |
Song, Y | 3 |
Spurgeon, SE | 2 |
Storring, JM | 1 |
Walewski, J | 1 |
Zhu, J | 4 |
Qin, R | 1 |
Henninger, T | 2 |
Howes, A | 2 |
Le Gouill, S | 5 |
Dreyling, M | 12 |
Killock, D | 2 |
Freeman, CL | 1 |
Pararajalingam, P | 1 |
Jin, L | 1 |
Balasubramanian, S | 2 |
Jiang, A | 1 |
Xu, W | 3 |
Grau, M | 1 |
Zapukhlyak, M | 1 |
Boyle, M | 1 |
Hodkinson, B | 1 |
Schaffer, M | 1 |
Enny, C | 3 |
Sun, S | 3 |
Vermeulen, J | 6 |
Morin, RD | 2 |
Scott, DW | 1 |
Lenz, G | 3 |
Rai, S | 1 |
Tanizawa, Y | 1 |
Cai, Z | 1 |
Huang, YJ | 1 |
Taipale, K | 1 |
Tajimi, M | 1 |
Cliff, ERS | 1 |
Dickinson, M | 1 |
Ferhanoglu, B | 1 |
Birtas Atesoglu, E | 1 |
Ozbalak, M | 1 |
Eşkazan, AE | 1 |
Vorobyev, VI | 2 |
Gemdzhian, EG | 1 |
Fedorova, LV | 1 |
Mikhailova, NB | 1 |
Ilyasov, RK | 1 |
Kaleikina, LP | 1 |
Trubyakova, OS | 1 |
Kaplanov, KD | 1 |
Melnichenko, EV | 1 |
Martynova, EV | 1 |
Yakovleva, EP | 1 |
Li, OY | 1 |
Tarasenko, EV | 1 |
Chumakova, EP | 1 |
Bulieva, NB | 1 |
Nesterova, ES | 1 |
Margolin, OV | 1 |
Zherebtsova, VA | 1 |
Butaev, LS | 1 |
Ptushkin, VV | 2 |
Araujo-Ayala, F | 1 |
Dobaño-López, C | 1 |
Valero, JG | 1 |
Gava, F | 1 |
Faria, C | 1 |
Norlund, M | 1 |
Morin, R | 1 |
Bernes-Lasserre, P | 1 |
Serrat, N | 1 |
Playa-Albinyana, H | 1 |
Giménez, R | 1 |
Lagarde, JM | 1 |
Colomer, D | 1 |
Bezombes, C | 1 |
Pérez-Galán, P | 1 |
Nishiyama-Fujita, Y | 1 |
Nakazato, T | 1 |
Ito, C | 1 |
Ogura, S | 1 |
Mizuno, K | 1 |
Kamiya, T | 1 |
Aisa, Y | 1 |
Mori, T | 1 |
Wang, HY | 4 |
Liu, X | 7 |
Nunez-Cruz, S | 3 |
Jillab, M | 1 |
Melnikov, O | 1 |
Nath, K | 2 |
Glickson, J | 1 |
Wasik, MA | 4 |
Jeon, YW | 1 |
Yoon, S | 1 |
Min, GJ | 1 |
Park, SS | 1 |
Park, S | 3 |
Yoon, JH | 1 |
Lee, SE | 1 |
Cho, BS | 1 |
Eom, KS | 1 |
Kim, YJ | 1 |
Kim, HJ | 2 |
Lee, S | 1 |
Min, CK | 1 |
Lee, JW | 1 |
Cho, SG | 4 |
Kabadi, SM | 4 |
Near, A | 1 |
Wada, K | 1 |
Burudpakdee, C | 1 |
Liang, SH | 1 |
Chiu, CF | 1 |
Bai, LY | 1 |
Telford, C | 1 |
Abhyankar, S | 1 |
Song, J | 2 |
Signorovitch, J | 1 |
Zhao, J | 1 |
Yao, Z | 1 |
Nakamura, K | 1 |
Saburi, M | 1 |
Kondo, Y | 1 |
Soga, Y | 1 |
Itani, K | 1 |
Kohno, K | 1 |
Otsuka, M | 1 |
Nakayama, T | 1 |
Zhou, X | 2 |
Steinhardt, MJ | 1 |
Düll, J | 1 |
Krummenast, F | 1 |
Danhof, S | 1 |
Meckel, K | 1 |
Nickel, K | 1 |
Grathwohl, D | 1 |
Leicht, HB | 1 |
Rosenwald, A | 4 |
Einsele, H | 1 |
Rasche, L | 1 |
Kortüm, M | 1 |
Schmelz, JL | 1 |
Cramer, F | 1 |
Romaguera, JE | 4 |
Mosna, K | 1 |
Ladicka, M | 1 |
Drgona, L | 1 |
Vranovska, M | 1 |
Hojsikova, I | 1 |
Tomasova, R | 1 |
Danihel, L | 1 |
Kyselovic, J | 1 |
Babal, P | 1 |
Hanna, KS | 1 |
Campbell, M | 1 |
Husak, A | 1 |
Sturm, S | 1 |
Halim, AA | 1 |
Alsayed, B | 1 |
Embarak, S | 1 |
Yaseen, T | 1 |
Dabbous, S | 1 |
Fontaine, O | 1 |
Dueluzeau, R | 1 |
Raibaud, P | 1 |
Chabanet, C | 1 |
Popoff, MR | 1 |
Badoual, J | 1 |
Gabilan, JC | 1 |
Andremont, A | 1 |
Gómez, L | 1 |
Andrés, S | 1 |
Sánchez, J | 1 |
Alonso, JM | 1 |
Rey, J | 1 |
López, F | 1 |
Yan, Z | 1 |
Zhou, L | 1 |
Zhao, Y | 3 |
Huang, L | 2 |
Hu, K | 1 |
Liu, H | 4 |
Wang, H | 3 |
Guo, Z | 1 |
Huang, H | 4 |
Yang, R | 1 |
Owen, TW | 1 |
Al-Kaysi, RO | 1 |
Bardeen, CJ | 1 |
Cheng, Q | 1 |
Cheng, T | 1 |
Wang, B | 4 |
Wu, X | 3 |
Ochiai, T | 1 |
Ishiguro, H | 2 |
Nakano, R | 2 |
Kubota, Y | 2 |
Hara, M | 1 |
Sunada, K | 1 |
Hashimoto, K | 1 |
Kajioka, J | 1 |
Fujishima, A | 1 |
Jiao, J | 4 |
Gai, QY | 3 |
Wang, W | 3 |
Zang, YP | 2 |
Niu, LL | 2 |
Fu, YJ | 3 |
Wang, X | 5 |
Yao, LP | 1 |
Qin, QP | 1 |
Wang, ZY | 1 |
Liu, J | 4 |
Aleksic Sabo, V | 1 |
Knezevic, P | 1 |
Borges-Argáez, R | 1 |
Chan-Balan, R | 1 |
Cetina-Montejo, L | 1 |
Ayora-Talavera, G | 1 |
Sansores-Peraza, P | 1 |
Gómez-Carballo, J | 1 |
Cáceres-Farfán, M | 1 |
Jang, J | 1 |
Akin, D | 1 |
Bashir, R | 1 |
Yu, Z | 1 |
Jiang, H | 4 |
He, C | 2 |
Xiao, Z | 1 |
Xu, J | 2 |
Sun, Q | 1 |
Han, D | 1 |
Lei, H | 1 |
Zhao, K | 2 |
Zhu, L | 1 |
Li, X | 5 |
Fu, H | 2 |
Wilson, BK | 1 |
Step, DL | 1 |
Maxwell, CL | 1 |
Gifford, CA | 1 |
Richards, CJ | 1 |
Krehbiel, CR | 1 |
Warner, JM | 1 |
Doerr, AJ | 1 |
Erickson, GE | 1 |
Guretzky, JA | 1 |
Rasby, RJ | 1 |
Watson, AK | 1 |
Klopfenstein, TJ | 1 |
Liu, Z | 3 |
Pham, TD | 1 |
Lee, BK | 1 |
Yang, FC | 1 |
Wu, KH | 1 |
Lin, WP | 1 |
Hu, MK | 1 |
Lin, L | 3 |
Shao, J | 1 |
Sun, M | 1 |
Zhang, X | 6 |
Xu, N | 1 |
Wang, R | 1 |
Liu, S | 1 |
He, H | 1 |
Dong, X | 2 |
Yang, M | 2 |
Yang, Q | 1 |
Duan, S | 1 |
Yu, Y | 2 |
Han, J | 2 |
Zhang, C | 3 |
Chen, L | 4 |
Yang, X | 1 |
Li, W | 3 |
Wang, T | 2 |
Campbell, DA | 1 |
Gao, K | 1 |
Zager, RA | 1 |
Johnson, ACM | 1 |
Guillem, A | 1 |
Keyser, J | 1 |
Singh, B | 1 |
Steubl, D | 1 |
Schneider, MP | 1 |
Meiselbach, H | 1 |
Nadal, J | 1 |
Schmid, MC | 1 |
Saritas, T | 1 |
Krane, V | 1 |
Sommerer, C | 1 |
Baid-Agrawal, S | 1 |
Voelkl, J | 1 |
Kotsis, F | 1 |
Köttgen, A | 1 |
Eckardt, KU | 1 |
Scherberich, JE | 1 |
Li, H | 4 |
Yao, L | 2 |
Sun, L | 3 |
Zhu, Z | 1 |
Naren, N | 1 |
Zhang, XX | 2 |
Gentile, GL | 1 |
Rupert, AS | 1 |
Carrasco, LI | 1 |
Garcia, EM | 1 |
Kumar, NG | 1 |
Walsh, SW | 1 |
Jefferson, KK | 1 |
Guest, RL | 1 |
Samé Guerra, D | 1 |
Wissler, M | 1 |
Grimm, J | 1 |
Silhavy, TJ | 1 |
Lee, JH | 3 |
Yoo, JS | 1 |
Kim, Y | 1 |
Kim, JS | 2 |
Lee, EJ | 1 |
Roe, JH | 1 |
Delorme, M | 1 |
Bouchard, PA | 1 |
Simon, M | 1 |
Simard, S | 1 |
Lellouche, F | 1 |
D'Urzo, KA | 1 |
Mok, F | 1 |
D'Urzo, AD | 1 |
Koneru, B | 1 |
Lopez, G | 1 |
Farooqi, A | 1 |
Conkrite, KL | 1 |
Nguyen, TH | 1 |
Macha, SJ | 1 |
Modi, A | 1 |
Rokita, JL | 1 |
Urias, E | 1 |
Hindle, A | 1 |
Davidson, H | 1 |
Mccoy, K | 1 |
Nance, J | 1 |
Yazdani, V | 1 |
Irwin, MS | 1 |
Yang, S | 2 |
Wheeler, DA | 1 |
Maris, JM | 1 |
Diskin, SJ | 1 |
Reynolds, CP | 1 |
Abhilash, L | 1 |
Kalliyil, A | 1 |
Sheeba, V | 1 |
Hartley, AM | 2 |
Meunier, B | 2 |
Pinotsis, N | 1 |
Maréchal, A | 2 |
Xu, JY | 1 |
Genko, N | 1 |
Haraux, F | 1 |
Rich, PR | 1 |
Kamalanathan, M | 1 |
Doyle, SM | 1 |
Xu, C | 1 |
Achberger, AM | 1 |
Wade, TL | 1 |
Schwehr, K | 1 |
Santschi, PH | 1 |
Sylvan, JB | 1 |
Quigg, A | 1 |
Leong, W | 1 |
Gao, S | 1 |
Zhai, X | 1 |
Wang, C | 2 |
Gilson, E | 1 |
Ye, J | 1 |
Lu, Y | 1 |
Yan, R | 1 |
Zhang, Y | 6 |
Hu, Z | 1 |
You, Q | 1 |
Cai, Q | 1 |
Yang, D | 1 |
Gu, S | 1 |
Dai, H | 1 |
Zhao, X | 6 |
Gui, C | 1 |
Gui, J | 1 |
Wu, PK | 1 |
Hong, SK | 1 |
Starenki, D | 1 |
Oshima, K | 1 |
Shao, H | 1 |
Gestwicki, JE | 1 |
Tsai, S | 1 |
Park, JI | 1 |
Wang, Y | 8 |
Gu, Z | 1 |
Dong, C | 2 |
Guo, G | 1 |
Li, L | 7 |
Barrett, HE | 1 |
Meester, EJ | 1 |
van Gaalen, K | 1 |
van der Heiden, K | 1 |
Krenning, BJ | 1 |
Beekman, FJ | 1 |
de Blois, E | 1 |
de Swart, J | 1 |
Verhagen, HJ | 1 |
Maina, T | 1 |
Nock, BA | 1 |
Norenberg, JP | 1 |
de Jong, M | 1 |
Gijsen, FJH | 1 |
Bernsen, MR | 1 |
Martínez-Milla, J | 1 |
Galán-Arriola, C | 1 |
Carnero, M | 1 |
Cobiella, J | 1 |
Pérez-Camargo, D | 1 |
Bautista-Hernández, V | 1 |
Rigol, M | 1 |
Solanes, N | 1 |
Villena-Gutierrez, R | 1 |
Lobo, M | 1 |
Mateo, J | 1 |
Vilchez-Tschischke, JP | 1 |
Salinas, B | 1 |
Cussó, L | 1 |
López, GJ | 1 |
Fuster, V | 1 |
Desco, M | 1 |
Sanchez-González, J | 1 |
Ibanez, B | 1 |
van den Berg, P | 1 |
Schweitzer, DH | 1 |
van Haard, PMM | 1 |
Geusens, PP | 1 |
van den Bergh, JP | 1 |
Zhu, X | 1 |
Huang, X | 4 |
Xu, H | 2 |
Yang, G | 3 |
Lin, Z | 1 |
Salem, HF | 1 |
Nafady, MM | 1 |
Kharshoum, RM | 1 |
Abd El-Ghafar, OA | 1 |
Farouk, HO | 1 |
Domiciano, D | 1 |
Nery, FC | 1 |
de Carvalho, PA | 1 |
Prudente, DO | 1 |
de Souza, LB | 1 |
Chalfun-Júnior, A | 1 |
Paiva, R | 1 |
Marchiori, PER | 1 |
Lu, M | 2 |
An, Z | 1 |
Jiang, J | 2 |
Li, J | 9 |
Du, S | 1 |
Zhou, H | 1 |
Cui, J | 1 |
Wu, W | 3 |
Lian, Q | 1 |
Uddin Ahmad, Z | 1 |
Gang, DD | 1 |
Konggidinata, MI | 1 |
Gallo, AA | 1 |
Zappi, ME | 1 |
Yang, TWW | 1 |
Johari, Y | 1 |
Burton, PR | 1 |
Earnest, A | 1 |
Shaw, K | 1 |
Hare, JL | 1 |
Brown, WA | 1 |
Kim, GA | 1 |
Han, S | 1 |
Choi, GH | 1 |
Choi, J | 1 |
Lim, YS | 1 |
Gallo, A | 1 |
Cancelli, C | 1 |
Ceron, E | 1 |
Covino, M | 1 |
Capoluongo, E | 1 |
Pocino, K | 1 |
Ianiro, G | 1 |
Cammarota, G | 1 |
Gasbarrini, A | 1 |
Montalto, M | 1 |
Somasundar, Y | 1 |
Lu, IC | 1 |
Mills, MR | 1 |
Qian, LY | 1 |
Olivares, X | 1 |
Ryabov, AD | 1 |
Collins, TJ | 1 |
Zhao, L | 1 |
Doddipatla, S | 1 |
Thomas, AM | 1 |
Nikolayev, AA | 1 |
Galimova, GR | 1 |
Azyazov, VN | 1 |
Mebel, AM | 1 |
Kaiser, RI | 1 |
Guo, S | 1 |
Yang, P | 1 |
Yu, X | 2 |
Wu, Y | 2 |
Zhang, H | 7 |
Yu, B | 2 |
Han, B | 1 |
George, MW | 1 |
Moor, MB | 1 |
Bonny, O | 1 |
Langenberg, E | 1 |
Paik, H | 1 |
Smith, EH | 1 |
Nair, HP | 1 |
Hanke, I | 1 |
Ganschow, S | 1 |
Catalan, G | 1 |
Domingo, N | 1 |
Schlom, DG | 1 |
Assefa, MK | 1 |
Wu, G | 2 |
Hayton, TW | 1 |
Becker, B | 1 |
Enikeev, D | 1 |
Netsch, C | 1 |
Gross, AJ | 1 |
Laukhtina, E | 1 |
Glybochko, P | 1 |
Rapoport, L | 1 |
Herrmann, TRW | 1 |
Taratkin, M | 1 |
Dai, W | 1 |
Shi, J | 2 |
Carreno, J | 1 |
Kloner, RA | 1 |
Pickersgill, NA | 1 |
Vetter, JM | 1 |
Kim, EH | 1 |
Cope, SJ | 1 |
Du, K | 1 |
Venkatesh, R | 1 |
Giardina, JD | 1 |
Saad, NES | 1 |
Bhayani, SB | 1 |
Figenshau, RS | 1 |
Eriksson, J | 1 |
Landfeldt, E | 1 |
Ireland, S | 1 |
Jackson, C | 1 |
Wyatt, E | 1 |
Gaudig, M | 1 |
Stancill, JS | 1 |
Happ, JT | 1 |
Broniowska, KA | 1 |
Hogg, N | 1 |
Corbett, JA | 1 |
Tang, LF | 1 |
Bi, YL | 1 |
Fan, Y | 2 |
Sun, YB | 1 |
Wang, AL | 1 |
Xiao, BH | 1 |
Wang, LF | 1 |
Qiu, SW | 1 |
Guo, SW | 1 |
Wáng, YXJ | 1 |
Sun, J | 4 |
Chu, S | 1 |
Pan, Q | 1 |
Li, D | 2 |
Zheng, S | 2 |
Ma, L | 1 |
Hu, T | 1 |
Wang, F | 2 |
Han, Z | 1 |
Yin, Z | 1 |
Ge, X | 1 |
Xie, K | 1 |
Lei, P | 1 |
Dias-Santagata, D | 1 |
Lennerz, JK | 1 |
Sadow, PM | 1 |
Frazier, RP | 1 |
Govinda Raju, S | 1 |
Henry, D | 1 |
Chung, T | 1 |
Kherani, J | 1 |
Rothenberg, SM | 1 |
Wirth, LJ | 1 |
Marti, CN | 1 |
Choi, NG | 1 |
Bae, SJ | 1 |
Ni, L | 1 |
Luo, X | 1 |
Dai, T | 1 |
Yang, Y | 3 |
Lee, R | 1 |
Fleischer, AS | 1 |
Wemhoff, AP | 1 |
Ford, CR | 1 |
Kleppinger, EL | 1 |
Helms, K | 1 |
Bush, AA | 1 |
Luna-Abanto, J | 1 |
García Ruiz, L | 1 |
Laura Martinez, J | 1 |
Álvarez Larraondo, M | 1 |
Villoslada Terrones, V | 1 |
Dukic, L | 1 |
Maric, N | 1 |
Simundic, AM | 1 |
Chogtu, B | 1 |
Ommurugan, B | 1 |
Thomson, SR | 1 |
Kalthur, SG | 1 |
Benidir, M | 1 |
El Massoudi, S | 1 |
El Ghadraoui, L | 1 |
Lazraq, A | 1 |
Benjelloun, M | 1 |
Errachidi, F | 1 |
Cassar, M | 1 |
Law, AD | 1 |
Chow, ES | 1 |
Giebultowicz, JM | 1 |
Kretzschmar, D | 1 |
Salonurmi, T | 1 |
Nabil, H | 1 |
Ronkainen, J | 1 |
Hyötyläinen, T | 1 |
Hautajärvi, H | 1 |
Savolainen, MJ | 1 |
Tolonen, A | 1 |
Orešič, M | 1 |
Känsäkoski, P | 1 |
Rysä, J | 1 |
Hakkola, J | 1 |
Hukkanen, J | 1 |
Zhu, N | 1 |
Li, Y | 6 |
Du, Q | 1 |
Hao, P | 1 |
Cao, X | 1 |
Li, CX | 1 |
Luo, XM | 1 |
Feng, JX | 1 |
Gonzalez-Cotto, M | 1 |
Guo, L | 2 |
Karwan, M | 1 |
Sen, SK | 1 |
Barb, J | 1 |
Collado, CJ | 1 |
Elloumi, F | 1 |
Palmieri, EM | 1 |
Boelte, K | 1 |
Kolodgie, FD | 1 |
Finn, AV | 1 |
Biesecker, LG | 1 |
McVicar, DW | 1 |
Qu, F | 1 |
Deng, Z | 1 |
Xie, Y | 2 |
Tang, J | 3 |
Luo, W | 1 |
Xiong, D | 1 |
Zhao, D | 2 |
Fang, J | 1 |
Zhou, Z | 1 |
Niu, PP | 1 |
Song, B | 1 |
Xu, YM | 1 |
Zhang, Z | 2 |
Qiu, N | 1 |
Yin, J | 1 |
Zhang, J | 4 |
Guo, W | 1 |
Liu, T | 3 |
Chen, D | 5 |
Luo, K | 1 |
He, Z | 2 |
Zheng, G | 1 |
Xu, F | 1 |
Sun, W | 1 |
Yin, F | 1 |
van Hest, JCM | 1 |
Du, L | 2 |
Shi, X | 1 |
Kang, S | 1 |
Duan, W | 1 |
Zhang, S | 4 |
Feng, J | 2 |
Qi, N | 1 |
Shen, G | 1 |
Ren, H | 1 |
Shang, Q | 1 |
Zhao, W | 2 |
Yang, Z | 3 |
Jiang, X | 2 |
Alame, M | 1 |
Cornillot, E | 1 |
Cacheux, V | 1 |
Tosato, G | 1 |
Four, M | 1 |
De Oliveira, L | 1 |
Gofflot, S | 1 |
Delvenne, P | 1 |
Turtoi, E | 1 |
Cabello-Aguilar, S | 1 |
Nishiyama, M | 1 |
Turtoi, A | 1 |
Costes-Martineau, V | 1 |
Colinge, J | 1 |
Guo, Q | 1 |
Quan, M | 1 |
Dong, J | 1 |
Bai, J | 1 |
Han, R | 1 |
Cai, Y | 1 |
Lv, YQ | 1 |
Chen, Q | 1 |
Lyu, HD | 1 |
Deng, L | 1 |
Zhou, D | 1 |
Xiao, X | 1 |
De Langhe, S | 1 |
Billadeau, DD | 1 |
Lou, Z | 1 |
Zhang, JS | 1 |
Xue, Z | 1 |
Shen, XD | 1 |
Gao, F | 1 |
Busuttil, RW | 1 |
Kupiec-Weglinski, JW | 1 |
Ji, H | 1 |
Otano, I | 1 |
Alvarez, M | 1 |
Minute, L | 1 |
Ochoa, MC | 1 |
Migueliz, I | 1 |
Molina, C | 1 |
Azpilikueta, A | 1 |
de Andrea, CE | 1 |
Etxeberria, I | 1 |
Sanmamed, MF | 1 |
Teijeira, Á | 1 |
Berraondo, P | 1 |
Melero, I | 1 |
Zhong, Z | 1 |
Xie, X | 1 |
Yu, Q | 1 |
Zhou, C | 1 |
Liu, C | 2 |
Liu, W | 2 |
Chen, W | 5 |
Yin, Y | 1 |
Li, CW | 1 |
Hsu, JL | 1 |
Zhou, Q | 1 |
Hu, B | 1 |
Fu, P | 1 |
Atyah, M | 1 |
Ma, Q | 2 |
Xu, Y | 1 |
Dong, Q | 1 |
Hung, MC | 1 |
Ren, N | 1 |
Huang, P | 1 |
Liao, R | 1 |
Chen, X | 3 |
Cao, Q | 1 |
Yuan, X | 1 |
Nie, W | 1 |
Yang, J | 2 |
Shao, B | 1 |
Ma, X | 1 |
Bi, Z | 1 |
Liang, X | 1 |
Tie, Y | 1 |
Mo, F | 1 |
Xie, D | 1 |
Wei, Y | 1 |
Wei, X | 2 |
Dokla, EME | 1 |
Fang, CS | 1 |
Chu, PC | 1 |
Chang, CS | 1 |
Abouzid, KAM | 1 |
Chen, CS | 1 |
Blaszczyk, R | 1 |
Brzezinska, J | 1 |
Dymek, B | 1 |
Stanczak, PS | 1 |
Mazurkiewicz, M | 1 |
Olczak, J | 1 |
Nowicka, J | 1 |
Dzwonek, K | 1 |
Zagozdzon, A | 1 |
Golab, J | 1 |
Golebiowski, A | 1 |
Xin, Z | 1 |
Himmelbauer, MK | 1 |
Jones, JH | 1 |
Enyedy, I | 1 |
Gilfillan, R | 1 |
Hesson, T | 1 |
King, K | 1 |
Marcotte, DJ | 1 |
Murugan, P | 1 |
Santoro, JC | 1 |
Gonzalez-Lopez de Turiso, F | 1 |
Pedron, J | 1 |
Boudot, C | 1 |
Brossas, JY | 1 |
Pinault, E | 1 |
Bourgeade-Delmas, S | 1 |
Sournia-Saquet, A | 1 |
Boutet-Robinet, E | 1 |
Destere, A | 1 |
Tronnet, A | 1 |
Bergé, J | 1 |
Bonduelle, C | 1 |
Deraeve, C | 1 |
Pratviel, G | 1 |
Stigliani, JL | 1 |
Paris, L | 1 |
Mazier, D | 1 |
Corvaisier, S | 1 |
Since, M | 1 |
Malzert-Fréon, A | 1 |
Wyllie, S | 1 |
Milne, R | 1 |
Fairlamb, AH | 1 |
Valentin, A | 1 |
Courtioux, B | 1 |
Verhaeghe, P | 1 |
Fang, X | 1 |
Gao, M | 1 |
Gao, H | 1 |
Bi, W | 1 |
Tang, H | 1 |
Cui, Y | 1 |
Zhang, L | 17 |
Fan, H | 1 |
Yu, H | 1 |
Mathison, CJN | 1 |
Chianelli, D | 1 |
Rucker, PV | 1 |
Nelson, J | 1 |
Roland, J | 1 |
Huang, Z | 2 |
Xie, YF | 1 |
Epple, R | 1 |
Bursulaya, B | 1 |
Lee, C | 1 |
Gao, MY | 1 |
Shaffer, J | 1 |
Briones, S | 1 |
Sarkisova, Y | 1 |
Galkin, A | 1 |
Li, N | 1 |
Li, C | 4 |
Hua, S | 1 |
Kasibhatla, S | 1 |
Kinyamu-Akunda, J | 1 |
Kikkawa, R | 1 |
Molteni, V | 1 |
Tellew, JE | 1 |
Jin, X | 1 |
Pang, B | 1 |
Liu, Q | 2 |
Huang, Y | 2 |
Josephine Fauci, A | 1 |
Ma, Y | 1 |
Soo Lee, M | 1 |
Yuan, W | 1 |
Gao, R | 1 |
Qi, H | 1 |
Zheng, W | 1 |
Yang, F | 2 |
Chua, H | 1 |
Wang, K | 1 |
Ou, Y | 1 |
Huang, M | 1 |
Zhu, Y | 1 |
Yu, J | 1 |
Tian, J | 1 |
Zhao, M | 1 |
Hu, J | 1 |
Yao, C | 1 |
Zhang, B | 1 |
Usawachintachit, M | 1 |
Tzou, DT | 1 |
Washington, SL | 1 |
Hu, W | 1 |
Chi, T | 1 |
Sorensen, MD | 1 |
Bailey, MR | 1 |
Hsi, RS | 1 |
Cunitz, BW | 1 |
Simon, J | 1 |
Wang, YN | 1 |
Dunmire, BL | 1 |
Paun, M | 1 |
Starr, F | 1 |
Lu, W | 1 |
Evan, AP | 1 |
Harper, JD | 1 |
Han, G | 2 |
Rodrigues, AE | 1 |
Fouladvand, F | 1 |
Falahi, E | 1 |
Asbaghi, O | 1 |
Abbasnezhad, A | 1 |
Anigboro, AA | 1 |
Avwioroko, OJ | 1 |
Cholu, CO | 1 |
Sonei, A | 1 |
Fazelipour, S | 1 |
Kanaani, L | 1 |
Jahromy, MH | 1 |
Jo, K | 1 |
Hong, KB | 1 |
Suh, HJ | 1 |
Park, JH | 1 |
Shin, E | 1 |
Park, E | 1 |
Kouakou-Kouamé, CA | 1 |
N'guessan, FK | 1 |
Montet, D | 1 |
Djè, MK | 1 |
Kim, GD | 1 |
González-Fernández, D | 1 |
Pons, EDC | 1 |
Rueda, D | 1 |
Sinisterra, OT | 1 |
Murillo, E | 1 |
Scott, ME | 1 |
Koski, KG | 1 |
Shete, PB | 1 |
Gonzales, R | 1 |
Ackerman, S | 1 |
Cattamanchi, A | 1 |
Handley, MA | 1 |
Li, XX | 1 |
Xiao, SZ | 1 |
Gu, FF | 1 |
He, WP | 1 |
Ni, YX | 1 |
Han, LZ | 1 |
Heffernan, JK | 1 |
Valgepea, K | 1 |
de Souza Pinto Lemgruber, R | 1 |
Casini, I | 1 |
Plan, M | 1 |
Tappel, R | 1 |
Simpson, SD | 1 |
Köpke, M | 1 |
Nielsen, LK | 1 |
Marcellin, E | 1 |
Cen, YK | 1 |
Lin, JG | 1 |
Wang, YL | 6 |
Wang, JY | 1 |
Liu, ZQ | 1 |
Zheng, YG | 1 |
Spirk, D | 1 |
Noll, S | 1 |
Burnier, M | 1 |
Rimoldi, S | 1 |
Noll, G | 1 |
Sudano, I | 1 |
Penzhorn, BL | 1 |
Oosthuizen, MC | 1 |
Kobos, LM | 1 |
Alqatani, S | 1 |
Ferreira, CR | 1 |
Aryal, UK | 1 |
Hedrick, V | 1 |
Sobreira, TJP | 1 |
Shannahan, JH | 1 |
Gale, P | 1 |
Singhroy, DN | 1 |
MacLean, E | 1 |
Kohli, M | 1 |
Lessem, E | 1 |
Branigan, D | 1 |
England, K | 1 |
Suleiman, K | 1 |
Drain, PK | 1 |
Ruhwald, M | 1 |
Schumacher, S | 1 |
Denkinger, CM | 1 |
Waning, B | 1 |
Van Gemert, W | 1 |
Pai, M | 1 |
Myers, RK | 1 |
Bonsu, JM | 1 |
Carey, ME | 1 |
Yerys, BE | 1 |
Mollen, CJ | 1 |
Curry, AE | 1 |
Douglas, TA | 1 |
Alinezhadbalalami, N | 1 |
Balani, N | 1 |
Schmelz, EM | 1 |
Davalos, RV | 1 |
Kamaldinov, T | 1 |
Erndt-Marino, J | 1 |
Levin, M | 1 |
Kaplan, DL | 1 |
Hahn, MS | 1 |
Heidarimoghadam, R | 1 |
Farmany, A | 1 |
Lee, JJ | 1 |
Kang, J | 1 |
Cho, JH | 1 |
Oh, S | 1 |
Park, DJ | 1 |
Perez-Maldonado, R | 1 |
Cho, JY | 1 |
Park, IH | 1 |
Kim, HB | 1 |
Song, M | 1 |
Mfarrej, B | 1 |
Jofra, T | 1 |
Morsiani, C | 1 |
Gagliani, N | 1 |
Fousteri, G | 1 |
Battaglia, M | 1 |
Giuliano, C | 1 |
Levinger, I | 1 |
Vogrin, S | 1 |
Neil, CJ | 1 |
Allen, JD | 1 |
Lv, Y | 1 |
Yuan, R | 1 |
Cai, B | 1 |
Bahrami, B | 1 |
Chowdhury, AH | 1 |
Yang, C | 2 |
Qiao, Q | 1 |
Liu, SF | 1 |
Zhang, WH | 1 |
Kolano, L | 1 |
Knappe, D | 1 |
Volke, D | 1 |
Sträter, N | 1 |
Hoffmann, R | 1 |
Coussens, M | 1 |
Calders, P | 1 |
Lapauw, B | 1 |
Celie, B | 1 |
Banica, T | 1 |
De Wandele, I | 1 |
Pacey, V | 1 |
Malfait, F | 1 |
Rombaut, L | 1 |
Vieira, D | 1 |
Angel, S | 1 |
Honjol, Y | 1 |
Gruenheid, S | 1 |
Gbureck, U | 1 |
Harvey, E | 1 |
Merle, G | 1 |
Seo, G | 1 |
Lee, G | 1 |
Kim, MJ | 1 |
Baek, SH | 1 |
Choi, M | 1 |
Ku, KB | 1 |
Lee, CS | 2 |
Jun, S | 1 |
Park, D | 1 |
Kim, HG | 1 |
Lee, JO | 2 |
Kim, BT | 1 |
Park, EC | 1 |
Kim, SI | 1 |
Ende, M | 1 |
Kirkkala, T | 1 |
Loitzenbauer, M | 1 |
Talla, D | 1 |
Wildner, M | 1 |
Miletich, R | 1 |
Criado, A | 1 |
Lavela, P | 1 |
Tirado, JL | 1 |
Pérez-Vicente, C | 1 |
Kang, D | 1 |
Feng, D | 2 |
Fang, Z | 1 |
Wei, F | 1 |
De Clercq, E | 1 |
Pannecouque, C | 1 |
Zhan, P | 1 |
Guo, Y | 2 |
Shen, Y | 1 |
Wang, Q | 3 |
Kawazoe, Y | 1 |
Jena, P | 1 |
Sun, Z | 1 |
Li, Z | 3 |
Liang, H | 1 |
Xu, X | 1 |
Ma, G | 1 |
Huo, X | 1 |
Church, JS | 1 |
Chace-Donahue, F | 1 |
Blum, JL | 1 |
Ratner, JR | 1 |
Zelikoff, JT | 1 |
Schwartzer, JJ | 1 |
Fiseha, T | 1 |
Tamir, Z | 1 |
Yao, W | 1 |
Wang, P | 1 |
Mi, K | 1 |
Cheng, J | 1 |
Gu, C | 1 |
Huang, J | 3 |
Sun, HB | 1 |
Xing, WQ | 1 |
Liu, XB | 1 |
Zheng, Y | 1 |
Yang, SJ | 1 |
Wang, ZF | 1 |
Liu, SL | 1 |
Ba, YF | 1 |
Zhang, RX | 1 |
Liu, BX | 1 |
Fan, CC | 1 |
Chen, PN | 1 |
Liang, GH | 1 |
Yu, YK | 1 |
Wang, HR | 1 |
Li, HM | 1 |
Li, ZX | 1 |
Lalani, SS | 1 |
Anasir, MI | 1 |
Poh, CL | 1 |
Khan, IT | 1 |
Nadeem, M | 1 |
Imran, M | 1 |
Khalique, A | 1 |
Raspini, B | 1 |
Porri, D | 1 |
De Giuseppe, R | 1 |
Chieppa, M | 1 |
Liso, M | 1 |
Cerbo, RM | 1 |
Civardi, E | 1 |
Garofoli, F | 1 |
Monti, MC | 1 |
Vacca, M | 1 |
De Angelis, M | 1 |
Cena, H | 1 |
Kong, D | 1 |
Han, X | 1 |
Zhou, Y | 4 |
Xue, H | 1 |
Zhang, W | 2 |
Ruan, Z | 1 |
Noer, PR | 1 |
Kjaer-Sorensen, K | 1 |
Juhl, AK | 1 |
Goldstein, A | 1 |
Ke, C | 1 |
Oxvig, C | 1 |
Duan, C | 1 |
Kong, F | 1 |
Lin, S | 1 |
Wang, Z | 2 |
Bhattacharya, R | 1 |
Mazumder, D | 1 |
Yan, X | 2 |
Ma, C | 1 |
Tang, Y | 1 |
Kong, X | 1 |
Lu, J | 1 |
Zhang, M | 1 |
Vital-Jacome, M | 1 |
Cazares-Granillo, M | 1 |
Carrillo-Reyes, J | 1 |
Buitron, G | 1 |
Jacob, SI | 1 |
Douair, I | 1 |
Maron, L | 1 |
Ménard, G | 1 |
Rusjan, P | 1 |
Sabioni, P | 1 |
Di Ciano, P | 1 |
Mansouri, E | 1 |
Boileau, I | 1 |
Laveillé, A | 1 |
Capet, M | 1 |
Duvauchelle, T | 1 |
Schwartz, JC | 1 |
Robert, P | 1 |
Le Foll, B | 1 |
Xia, Y | 1 |
Chen, S | 1 |
Luo, M | 1 |
Wu, J | 1 |
Cai, S | 1 |
He, Y | 2 |
Garbacz, P | 1 |
Misiak, M | 1 |
Jackowski, K | 1 |
Yuan, Q | 1 |
Sherrell, PC | 1 |
Chen, J | 2 |
Bi, X | 1 |
Nutho, B | 1 |
Mahalapbutr, P | 1 |
Hengphasatporn, K | 1 |
Pattaranggoon, NC | 1 |
Simanon, N | 1 |
Shigeta, Y | 1 |
Hannongbua, S | 1 |
Rungrotmongkol, T | 1 |
Caffrey, PJ | 1 |
Kher, R | 1 |
Bian, K | 1 |
Delaney, S | 1 |
Xue, J | 1 |
Wu, P | 1 |
Xu, L | 1 |
Yuan, Y | 1 |
Luo, J | 1 |
Ye, S | 1 |
Ustriyana, P | 1 |
Wei, B | 1 |
Raee, E | 1 |
Hu, Y | 1 |
Wesdemiotis, C | 1 |
Sahai, N | 1 |
Kaur, A | 1 |
Nigam, K | 1 |
Srivastava, S | 1 |
Tyagi, A | 1 |
Dang, S | 1 |
Millar, JE | 1 |
Bartnikowski, N | 1 |
Passmore, MR | 1 |
Obonyo, NG | 1 |
Malfertheiner, MV | 1 |
von Bahr, V | 1 |
Redd, MA | 1 |
See Hoe, L | 1 |
Ki, KK | 1 |
Pedersen, S | 1 |
Boyle, AJ | 1 |
Baillie, JK | 1 |
Shekar, K | 1 |
Palpant, N | 1 |
Suen, JY | 1 |
Matthay, MA | 1 |
McAuley, DF | 1 |
Fraser, JF | 1 |
Settles, JA | 1 |
Gerety, GF | 1 |
Spaepen, E | 1 |
Suico, JG | 1 |
Child, CJ | 1 |
Oh, BL | 1 |
Lee, JS | 1 |
Lee, EY | 1 |
Lee, HY | 1 |
Yu, HG | 1 |
Leslie, I | 1 |
Boos, LA | 1 |
Larkin, J | 1 |
Pickering, L | 1 |
Lima, HK | 1 |
Vogel, K | 1 |
Hampel, D | 1 |
Wagner-Gillespie, M | 1 |
Fogleman, AD | 1 |
Ferraz, SL | 1 |
O'Connor, M | 1 |
Mazzucchelli, TG | 1 |
Kajiyama, H | 1 |
Suzuki, S | 1 |
Shimbo, A | 1 |
Utsumi, F | 1 |
Yoshikawa, N | 1 |
Kikkawa, F | 1 |
Javvaji, PK | 1 |
Dhali, A | 1 |
Francis, JR | 1 |
Kolte, AP | 1 |
Roy, SC | 1 |
Selvaraju, S | 1 |
Mech, A | 1 |
Sejian, V | 1 |
DeSilva, S | 1 |
Vaidya, SS | 1 |
Mao, C | 1 |
Akhatayeva, Z | 1 |
Cheng, H | 1 |
Zhang, G | 1 |
Jiang, F | 1 |
Meng, X | 1 |
Elnour, IE | 1 |
Lan, X | 1 |
Song, E | 1 |
Rohde, S | 1 |
Antonides, CFJ | 1 |
Muslem, R | 1 |
de Woestijne, PCV | 1 |
der Meulen, MHV | 1 |
Kraemer, US | 1 |
Dalinghaus, M | 1 |
Bogers, AJJC | 1 |
Pourmand, A | 1 |
Ghassemi, M | 1 |
Sumon, K | 1 |
Amini, SB | 1 |
Hood, C | 1 |
Sikka, N | 1 |
Duan, H | 1 |
Chen, WP | 1 |
Fan, M | 1 |
Wang, WP | 1 |
Yu, L | 1 |
Tan, SJ | 1 |
Xin, S | 1 |
Wan, LJ | 1 |
Guo, YG | 1 |
Tanda, S | 1 |
Gingl, K | 1 |
Ličbinský, R | 1 |
Hegrová, J | 1 |
Goessler, W | 1 |
Li, ZL | 1 |
Zhou, YL | 1 |
Yan, W | 1 |
Luo, L | 1 |
Su, ZZ | 1 |
Fan, MZ | 1 |
Wang, SR | 1 |
Zhao, WG | 1 |
Xu, D | 1 |
Hassan, HM | 1 |
Jiang, Z | 1 |
Bachmann, KF | 1 |
Haenggi, M | 1 |
Jakob, SM | 1 |
Takala, J | 1 |
Gattinoni, L | 1 |
Berger, D | 1 |
Bentley, RF | 1 |
Vecchiarelli, E | 1 |
Banks, L | 1 |
Gonçalves, PEO | 1 |
Thomas, SG | 1 |
Goodman, JM | 1 |
Mather, K | 1 |
Boachie, R | 1 |
Anini, Y | 1 |
Panahi, S | 1 |
Anderson, GH | 1 |
Luhovyy, BL | 1 |
Nafie, MS | 1 |
Arafa, K | 1 |
Sedky, NK | 1 |
Alakhdar, AA | 1 |
Arafa, RK | 1 |
Fan, S | 1 |
Hu, H | 1 |
Liang, J | 1 |
Hu, BC | 1 |
Wen, Z | 1 |
Hu, D | 1 |
Liu, YY | 1 |
Chu, Q | 1 |
Wu, MC | 1 |
Lu, X | 1 |
Wang, D | 1 |
Hu, M | 1 |
Shen, H | 1 |
Yao, M | 1 |
Dahlgren, RA | 1 |
Vysloužil, J | 1 |
Kulich, P | 1 |
Zeman, T | 1 |
Vaculovič, T | 1 |
Tvrdoňová, M | 1 |
Mikuška, P | 1 |
Večeřa, Z | 1 |
Stráská, J | 1 |
Moravec, P | 1 |
Balcar, VJ | 1 |
Šerý, O | 1 |
Qiao, L | 1 |
Xiong, X | 1 |
Peng, X | 1 |
Zheng, J | 1 |
Duan, J | 1 |
Xiao, W | 1 |
Zhou, HY | 1 |
Sui, ZY | 1 |
Zhao, FL | 1 |
Sun, YN | 1 |
Han, BH | 1 |
Jintao, X | 1 |
Shasha, Y | 1 |
Jincai, W | 1 |
Chunyan, L | 1 |
Mengya, Y | 1 |
Yongli, S | 1 |
Rasoanirina, BNV | 1 |
Lassoued, MA | 1 |
Miladi, K | 1 |
Razafindrakoto, Z | 1 |
Chaâbane-Banaoues, R | 1 |
Ramanitrahasimbola, D | 1 |
Cornet, M | 1 |
Sfar, S | 1 |
Liang, C | 1 |
Xing, Q | 1 |
Yi, JL | 1 |
Zhang, YQ | 1 |
Li, CY | 1 |
Tang, SJ | 1 |
Gao, C | 1 |
Sun, X | 1 |
Peng, M | 1 |
Sun, XF | 1 |
Zhang, T | 1 |
Shi, JH | 1 |
Liao, CX | 1 |
Gao, WJ | 1 |
Sun, LL | 1 |
Gao, Y | 1 |
Cao, WH | 1 |
Lyu, J | 1 |
Yu, CQ | 1 |
Wang, SF | 1 |
Pang, ZC | 1 |
Cong, LM | 1 |
Dong, Z | 1 |
Wu, F | 1 |
Wu, XP | 1 |
Jiang, GH | 1 |
Wang, XJ | 1 |
Wang, BY | 1 |
Li, LM | 1 |
Pan, L | 1 |
Wan, SP | 1 |
Yi, HWL | 1 |
He, HJ | 1 |
Yong, ZP | 1 |
Shan, GL | 1 |
Weng, TT | 1 |
Yan, SQ | 1 |
Gao, GP | 1 |
Wei, C | 1 |
Tao, FB | 1 |
Shao, ZH | 1 |
Yao, T | 1 |
Dong, S | 1 |
Shi, S | 1 |
Feng, YL | 1 |
Zhang, YW | 1 |
Wang, SP | 1 |
Shi, AX | 1 |
Operario, D | 1 |
Zhang, ZH | 1 |
Zhu, XF | 1 |
Zaller, N | 1 |
Gao, P | 1 |
Sun, YH | 1 |
Zhang, HB | 1 |
Terao, T | 1 |
Narita, K | 1 |
Tsushima, T | 1 |
Miura, D | 1 |
Takeuchi, M | 1 |
Matsue, K | 1 |
Tucker, D | 1 |
Morley, N | 2 |
MacLean, P | 1 |
Vandenberghe, E | 2 |
Booth, S | 1 |
Parisi, L | 2 |
Rule, S | 14 |
Dmitrieva, EA | 1 |
Nikitin, EA | 1 |
Ignatova, AA | 1 |
Poletaev, AV | 1 |
Seregina, EA | 1 |
Voronin, KA | 1 |
Polokhov, DM | 1 |
Maschan, AA | 1 |
Novichkova, GA | 1 |
Panteleev, MA | 1 |
Orlando, EJ | 1 |
Bogusz, AM | 1 |
Lacey, SF | 2 |
Strauser, HT | 1 |
Nejati, R | 1 |
Zhang, P | 1 |
Brooks, S | 1 |
Watt, C | 1 |
Melenhorst, JJ | 1 |
June, CH | 2 |
Schuster, SJ | 4 |
Scapinello, G | 1 |
Riva, M | 1 |
Branca, A | 1 |
Pizzi, M | 1 |
Bonaldi, L | 1 |
Martines, A | 1 |
Manni, S | 1 |
Visentin, A | 1 |
Trentin, L | 1 |
Semenzato, G | 1 |
Gurrieri, C | 1 |
Piazza, F | 1 |
Higer, M | 1 |
Cana, D | 1 |
Podlech, J | 1 |
Schadmand-Fischer, S | 1 |
Schwarting, A | 1 |
Teschner, D | 1 |
Theobald, M | 1 |
Wölfel, T | 1 |
Hess, G | 7 |
de Jong, J | 2 |
Mitselos, A | 1 |
Cordoba, R | 1 |
Panizo, C | 1 |
Wrobel, T | 1 |
Dlugosz-Danecka, M | 2 |
Sukbuntherng, J | 2 |
Ouellet, D | 1 |
Hellemans, P | 1 |
Davis, JE | 1 |
Handunnetti, SM | 1 |
Ludford-Menting, M | 1 |
Sharpe, C | 1 |
Blombery, P | 2 |
Anderson, MA | 4 |
Roberts, AW | 4 |
Seymour, JF | 7 |
Ritchie, DS | 1 |
Koldej, RM | 1 |
Hindilerden, F | 1 |
Yönal Hindilerden, İ | 1 |
Diz Küçükkaya, R | 1 |
Sharman, J | 2 |
Clark, J | 1 |
Andorsky, D | 1 |
Yasuda, H | 1 |
Tsukune, Y | 1 |
Inano, T | 1 |
Mori, Y | 1 |
Ota, Y | 1 |
Komatsu, N | 1 |
Okahashi, N | 1 |
Uchihara, M | 1 |
Hoshino, E | 1 |
Morschhauser, F | 1 |
Chiron, D | 4 |
Bouabdallah, K | 1 |
Cartron, G | 1 |
Casasnovas, O | 1 |
Bodet-Milin, C | 1 |
Ragot, S | 1 |
Bossard, C | 1 |
Nadal, N | 1 |
Herbaux, C | 1 |
Tessoulin, B | 2 |
Tchernonog, E | 1 |
Rossi, C | 1 |
McCulloch, R | 2 |
Gastinne, T | 1 |
Callanan, MB | 1 |
Danilov, AV | 2 |
Persky, DO | 2 |
Alsuliman, T | 1 |
Faict, S | 1 |
Malard, F | 1 |
Genthon, A | 1 |
Brissot, E | 1 |
Van de Wyngaert, Z | 1 |
Ikhlef, S | 1 |
Banet, A | 1 |
Lapusan, S | 1 |
Sestili, S | 1 |
Corre, E | 1 |
M'hammedi-Bouzina, F | 1 |
Schaeffer, L | 1 |
Legrand, O | 1 |
Dulery, R | 1 |
Mohty, M | 1 |
Marjanovic, Z | 1 |
Byfield, SD | 1 |
LE, L | 1 |
Olufade, T | 1 |
Maddocks, K | 5 |
Crosbie, N | 1 |
Eyre, TA | 1 |
Bolam, S | 1 |
Arasaretnam, A | 1 |
Creasey, T | 1 |
Goradia, H | 1 |
McMillan, A | 1 |
Dawi, S | 1 |
Harrison, S | 1 |
Miles, O | 1 |
Robinson, A | 1 |
Dutton, D | 1 |
Wilson, MR | 1 |
McKay, P | 1 |
Follows, G | 2 |
Phillips, N | 1 |
Patmore, R | 2 |
Lambert, J | 1 |
Osborne, W | 1 |
Johnston, R | 1 |
Kirkwood, AA | 1 |
Yi, JH | 1 |
Yoon, DH | 2 |
Suh, C | 2 |
Chang, MH | 1 |
Yang, DH | 1 |
Jo, JC | 1 |
Hyun, SY | 1 |
Eom, HS | 1 |
Kwon, JH | 1 |
Han, SH | 1 |
Lee, SS | 1 |
Kwak, JY | 1 |
Kim, SH | 1 |
Kim, DS | 1 |
Oh, SY | 1 |
Ryoo, HM | 1 |
Kim, WS | 1 |
Roulin, L | 1 |
Haioun, C | 1 |
Lemonnier, F | 1 |
Fuhr, V | 1 |
Vafadarnejad, E | 1 |
Dietrich, O | 1 |
Arampatzi, P | 1 |
Riedel, A | 1 |
Saliba, AE | 1 |
Rauert-Wunderlich, H | 3 |
Wang, MY | 1 |
Lwin, T | 3 |
Park, PM | 1 |
Gao, J | 1 |
Meads, MB | 2 |
Ren, Y | 2 |
Li, T | 1 |
Fahmi, NA | 1 |
Singh, S | 1 |
Sehgal, L | 1 |
Silva, AS | 1 |
Sotomayor, EM | 1 |
Shain, KH | 2 |
Cleveland, JL | 1 |
Qi, J | 2 |
Shah, BD | 1 |
Tao, J | 4 |
Kagiyama, Y | 1 |
Fujita, S | 1 |
Shima, Y | 1 |
Yamagata, K | 1 |
Katsumoto, T | 1 |
Nakagawa, M | 1 |
Honma, D | 1 |
Adachi, N | 1 |
Araki, K | 1 |
Kato, A | 1 |
Inaki, K | 1 |
Ono, Y | 1 |
Fukuhara, S | 1 |
Kobayashi, Y | 1 |
Tobinai, K | 3 |
Kitabayashi, I | 1 |
Deng, H | 1 |
Li, Q | 1 |
Pu, Y | 1 |
Qian, Z | 1 |
Leitinger, EJ | 1 |
Wright, RM | 1 |
Nelson, N | 1 |
Juneja, S | 1 |
Nowakowski, KE | 1 |
Abeykoon, JP | 1 |
Manske, M | 1 |
Stenson, MJ | 1 |
Timm, MM | 1 |
Hanson, CA | 1 |
Van Dyke, DL | 1 |
Dasari, S | 1 |
Witzig, TE | 1 |
Ghosh, N | 3 |
Emond, B | 1 |
Lafeuille, MH | 1 |
Côté-Sergent, A | 1 |
Lefebvre, P | 1 |
Huang, Q | 1 |
Nomie, K | 7 |
Bell, T | 3 |
Pham, L | 1 |
Kadri, S | 2 |
Segal, J | 1 |
Zhou, S | 3 |
Richard, S | 1 |
Sharma, S | 3 |
Oriabure, O | 2 |
Guo, H | 4 |
Tao, W | 1 |
Fang, B | 3 |
Ahmed, M | 5 |
Huang, SY | 1 |
Shao, Y | 1 |
Lam, L | 2 |
Yi, Q | 1 |
Srour, SA | 2 |
Romaguera, J | 4 |
Silva, A | 1 |
Shah, B | 4 |
Fu, K | 1 |
Bi, C | 1 |
Jacobson, T | 1 |
Silva, M | 1 |
Distler, A | 1 |
Darville, L | 1 |
Han, Y | 1 |
Rebatchouk, D | 1 |
Di Liberto, M | 3 |
Moscinski, LC | 1 |
Koomen, JM | 1 |
Dalton, WS | 1 |
Sotomayor, E | 1 |
Aw, A | 1 |
Brown, JR | 4 |
Murthy, V | 1 |
Weaving, S | 1 |
Paneesha, S | 1 |
Santucci Silva, R | 1 |
Rusconi, C | 3 |
Caballero, D | 3 |
Joao, C | 3 |
Witzens-Harig, M | 3 |
Bence-Bruckler, I | 3 |
Zhou, W | 2 |
Goldberg, JD | 3 |
Trambitas, C | 1 |
Traina, S | 2 |
Chiou, CF | 1 |
Diels, J | 1 |
Titus-Rains, KS | 1 |
Brown, JN | 1 |
Hammond, JM | 1 |
Conaway, MR | 1 |
Hagner, PR | 1 |
Chiu, H | 1 |
Ortiz, M | 1 |
Apollonio, B | 1 |
Couto, S | 1 |
Waldman, MF | 1 |
Flynt, E | 1 |
Ramsay, AG | 1 |
Trotter, M | 1 |
Gandhi, AK | 1 |
Chopra, R | 1 |
Thakurta, A | 1 |
Auer, R | 4 |
Kahl, B | 2 |
Cavazos, N | 1 |
Liu, B | 1 |
Clow, F | 3 |
Beaupre, D | 1 |
Wildgust, M | 1 |
Sudhakaran, S | 1 |
Bashoura, L | 1 |
Stewart, J | 2 |
Balachandran, DD | 1 |
Faiz, SA | 2 |
Law, YXT | 1 |
Lee, LS | 1 |
Vitagliano, O | 1 |
Trastulli, F | 1 |
Cacace, F | 1 |
Leone, S | 1 |
Memoli, M | 1 |
Scalia, G | 1 |
Notarangelo, M | 1 |
Mainolfi, CG | 1 |
De Renzo, A | 1 |
Pane, F | 1 |
Rudelius, M | 2 |
Rosenfeldt, MT | 1 |
Leich, E | 1 |
Solimando, AG | 1 |
Beilhack, A | 1 |
Ott, G | 2 |
Phillips, T | 2 |
Lossos, IS | 1 |
Hamadani, M | 2 |
Reeder, CB | 1 |
Barnett, E | 1 |
Bravo, MC | 1 |
Martin, P | 7 |
Lu, L | 1 |
Zhu, F | 1 |
Yang, DT | 1 |
Huang, W | 1 |
Safe, S | 1 |
Rui, L | 1 |
Hershkovitz-Rokah, O | 1 |
Pulver, D | 1 |
Shpilberg, O | 1 |
Li, G | 1 |
Moscinski, L | 1 |
Yu, M | 1 |
Ma, Z | 1 |
Jin, J | 2 |
Pan, J | 1 |
Li, F | 1 |
Eskelund, CW | 1 |
Hutchings, M | 1 |
Räty, R | 1 |
Wader, KF | 1 |
Laurell, A | 1 |
Toldbod, H | 1 |
Pedersen, LB | 1 |
Niemann, CU | 2 |
Dahl, C | 1 |
Kuitunen, H | 1 |
Geisler, CH | 1 |
Grønbæk, K | 1 |
Kolstad, A | 1 |
Restelli, V | 1 |
Lupi, M | 1 |
Vagni, M | 1 |
Chilà, R | 1 |
Bertoni, F | 3 |
Damia, G | 1 |
Carrassa, L | 1 |
Arora, PC | 1 |
Guan, J | 1 |
Huang, D | 1 |
Yakimchuk, K | 1 |
Okret, S | 1 |
Varughese, T | 1 |
Taur, Y | 1 |
Cohen, N | 1 |
Palomba, ML | 1 |
Seo, SK | 1 |
Hohl, TM | 1 |
Redelman-Sidi, G | 1 |
Smith, A | 1 |
Roman, E | 1 |
Appleton, S | 1 |
Howell, D | 1 |
Johnson, R | 1 |
Burton, C | 1 |
Trneny, M | 2 |
Offner, F | 2 |
Thieblemont, C | 5 |
Goldberg, J | 1 |
Curtis, A | 1 |
Rueter, J | 2 |
Rajan, S | 1 |
Shopland, L | 1 |
Pott, C | 2 |
Agarwal, R | 3 |
Handunnetti, S | 2 |
Hicks, RJ | 1 |
Burbury, K | 2 |
Turner, G | 1 |
Di Iulio, J | 1 |
Bressel, M | 1 |
Westerman, D | 1 |
Lade, S | 1 |
Dawson, SJ | 2 |
Dawson, MA | 3 |
Dreger, P | 1 |
Michallet, M | 1 |
Bosman, P | 1 |
Dietrich, S | 1 |
Sobh, M | 1 |
Boumendil, A | 1 |
Nagler, A | 1 |
Scheid, C | 1 |
Cornelissen, J | 1 |
Niederwieser, D | 1 |
Müller, L | 1 |
Scortechini, I | 1 |
Schoemans, H | 1 |
Andersen, NS | 1 |
Finke, J | 1 |
Russo, D | 1 |
Ljungman, P | 1 |
Passweg, J | 1 |
van Gelder, M | 1 |
Durakovic, N | 1 |
Labussiere-Wallet, H | 1 |
Berg, T | 1 |
Wulf, G | 1 |
Bethge, W | 1 |
Bunjes, D | 1 |
Stilgenbauer, S | 3 |
Canepari, ME | 1 |
Schaap, M | 1 |
Fox, CP | 1 |
Kröger, N | 1 |
Montoto, S | 1 |
Schetelig, J | 1 |
Awan, FT | 1 |
Tarapore, R | 1 |
Prabhu, V | 1 |
Allen, J | 1 |
Schalop, L | 1 |
Zloza, A | 1 |
Sadimin, ET | 1 |
Schenkel, J | 1 |
Hagemeister, F | 3 |
Westin, J | 2 |
Till, BG | 1 |
Shaikh, H | 1 |
Khattab, A | 1 |
Faisal, MS | 1 |
Chilkulwar, A | 1 |
Albrethsen, M | 1 |
Sadashiv, S | 1 |
Fazal, S | 1 |
Hillmen, P | 1 |
Fraser, G | 1 |
Burger, JA | 2 |
Dilhuydy, MS | 1 |
Moreno, C | 1 |
Cramer, P | 1 |
Liu, E | 1 |
Chang, S | 2 |
Styles, L | 1 |
James, DF | 1 |
Patel, K | 1 |
Graef, T | 1 |
Lee, J | 2 |
Zhang, LL | 1 |
Sukhanova, M | 2 |
Venkataraman, G | 1 |
Alikhan, M | 1 |
Lu, P | 4 |
Guo, A | 2 |
Galanina, N | 1 |
Andrade, J | 1 |
Ghorab, A | 1 |
Zeng, D | 2 |
Gong, T | 2 |
Neelapu, S | 1 |
Champlin, R | 2 |
Tappenden, P | 1 |
Simpson, E | 1 |
Hamilton, J | 1 |
Pollard, D | 1 |
Clowes, M | 1 |
Kaltenthaler, E | 1 |
Meiklejohn, D | 1 |
Yao, J | 1 |
Li, CJ | 1 |
Lorence, E | 3 |
Jiang, C | 1 |
Nomie, KJ | 1 |
da Cunha-Bang, C | 1 |
Dolgin, E | 1 |
Qi, K | 1 |
Sales De Gauzy, T | 1 |
Oberic, L | 1 |
Fournié, P | 1 |
Soler, V | 1 |
Chan, YC | 1 |
Hunter, T | 1 |
Vassiliadis, D | 1 |
Teh, CE | 1 |
Thijssen, R | 1 |
Yeh, P | 1 |
Wong, SQ | 1 |
Ftouni, S | 1 |
Lam, EYN | 1 |
Gilan, O | 1 |
Bell, CC | 1 |
Knezevic, K | 1 |
Rayeroux, K | 1 |
Zordan, A | 1 |
Huang, DCS | 1 |
Wall, M | 1 |
Gray, DHD | 1 |
Ming, M | 1 |
Xie, B | 1 |
Shacham, S | 1 |
Landesman, Y | 1 |
Maltsev, N | 1 |
Dobrovolsky, D | 1 |
Wang, ES | 1 |
Morrow, S | 1 |
Leahy, C | 1 |
Faust, T | 1 |
Nowak, RP | 1 |
Donovan, KA | 1 |
Fischer, ES | 1 |
Treon, SP | 1 |
Weinstock, DM | 2 |
Gray, NS | 1 |
Davids, MS | 1 |
Kim, HT | 1 |
Nicotra, A | 1 |
Savell, A | 1 |
Francoeur, K | 1 |
Hellman, JM | 1 |
Bazemore, J | 1 |
Miskin, HP | 1 |
Sportelli, P | 1 |
Stampleman, L | 1 |
Maegawa, R | 1 |
Boruchov, AM | 1 |
Arnason, JE | 1 |
Jacobson, CA | 1 |
Jacobsen, ED | 2 |
Fisher, DC | 1 |
Robak, T | 2 |
Mori, S | 1 |
Patel, RD | 1 |
Ahmad, S | 1 |
Varela, J | 1 |
Smith, T | 1 |
Altoos, R | 1 |
Shen, Q | 1 |
Goldstein, SC | 1 |
Morabito, F | 1 |
Skafi, M | 1 |
Recchia, AG | 1 |
Kashkeesh, A | 1 |
Hindiyeh, M | 1 |
Sabatleen, A | 1 |
Morabito, L | 1 |
Alijanazreh, H | 1 |
Hamamreh, Y | 1 |
Uchida, T | 2 |
Fukuhara, N | 2 |
Nishikawa, T | 2 |
Długosz-Danecka, M | 1 |
Tarantelli, C | 1 |
Curti, E | 1 |
Gaudio, E | 1 |
Spriano, F | 1 |
Priebe, V | 1 |
Cascione, L | 1 |
Arribas, AJ | 1 |
Zucca, E | 2 |
Rossi, D | 1 |
Stathis, A | 1 |
Bartlett, NL | 1 |
Blum, KA | 4 |
Ruan, J | 2 |
Ridling, L | 1 |
Dittus, C | 1 |
Inghirami, G | 1 |
DiLiberto, M | 2 |
Chen-Kiang, S | 4 |
Leonard, JP | 3 |
Jung, D | 1 |
Caldeira, D | 1 |
Alves, D | 1 |
Costa, J | 1 |
Ferreira, JJ | 1 |
Pinto, FJ | 1 |
Styskel, BA | 1 |
Lopez-Mattei, J | 1 |
Jimenez, CA | 1 |
D'Agaro, T | 1 |
Zucchetto, A | 1 |
Vit, F | 1 |
Bittolo, T | 1 |
Tissino, E | 1 |
Rossi, FM | 1 |
Degan, M | 1 |
Zaja, F | 1 |
Bulian, P | 1 |
Bo, MD | 1 |
Ladetto, M | 1 |
Zamò, A | 1 |
Gattei, V | 1 |
Bomben, R | 1 |
Ding, N | 1 |
Rao, Y | 1 |
Lee, SC | 1 |
Shestov, AA | 1 |
Roman, JC | 1 |
Pickup, S | 1 |
Hofbauer, S | 1 |
Mesaros, C | 1 |
Nelson, DS | 1 |
Blair, IA | 1 |
Glickson, JD | 1 |
Papin, A | 1 |
Bellanger, C | 1 |
Moreau, A | 1 |
Le Bris, Y | 1 |
Maisonneuve, H | 1 |
Moreau, P | 2 |
Touzeau, C | 2 |
Amiot, M | 2 |
Pellat-Deceunynck, C | 2 |
Schamroth Pravda, M | 1 |
Schamroth Pravda, N | 1 |
Lishner, M | 1 |
Di Francesco, ME | 1 |
Feng, N | 1 |
Haun, R | 1 |
Lan, R | 1 |
Mackintosh, SG | 1 |
Mao, X | 1 |
Song, X | 2 |
Pham, LV | 2 |
Lorenzi, PL | 1 |
Marszalek, J | 1 |
Heffernan, T | 1 |
Draetta, G | 1 |
Jones, P | 1 |
Futreal, A | 1 |
Choi, YJ | 1 |
Kim, DH | 1 |
Choi, CM | 1 |
Lee, JC | 1 |
Hong, JY | 1 |
Rho, JK | 1 |
Best, S | 1 |
Bruss, N | 1 |
Kittai, A | 1 |
Berger, A | 1 |
Flinsenberg, TWH | 1 |
Tromedjo, CC | 1 |
Hu, N | 1 |
Thia, KYT | 1 |
Noori, T | 1 |
Aw Yeang, HX | 1 |
Tantalo, DG | 1 |
Ritchie, D | 1 |
Koldej, R | 1 |
Neeson, PJ | 1 |
Trapani, JA | 1 |
Voskoboinik, I | 1 |
Bond, DA | 1 |
Alinari, L | 2 |
Fradley, MG | 1 |
Gliksman, M | 1 |
Emole, J | 1 |
Viganego, F | 1 |
Rhea, I | 1 |
Welter-Frost, A | 1 |
Armanious, M | 1 |
Lee, DH | 1 |
Walko, C | 1 |
Chavez, JC | 1 |
McLeod, H | 1 |
Pinilla-Ibarz, J | 1 |
Schabath, MB | 1 |
Buggy, JJ | 3 |
Newberry, KJ | 1 |
Advani, RH | 1 |
Barrientos, JC | 1 |
Chmielowska, E | 2 |
Radford, J | 1 |
Jedrzejczak, WW | 1 |
Johnson, P | 1 |
Newberry, K | 1 |
Ou, Z | 1 |
Cheng, N | 1 |
McGreivy, J | 3 |
Chang, BY | 2 |
Beaupre, DM | 2 |
Kunkel, LA | 1 |
Francesco, M | 1 |
De Rooij, MF | 2 |
Magadala, P | 1 |
Steggerda, SM | 1 |
Huang, MM | 1 |
Kuil, A | 2 |
Herman, SE | 2 |
Pals, ST | 2 |
Wilson, W | 1 |
Wiestner, A | 3 |
Spaargaren, M | 2 |
Elias, L | 1 |
Cinar, M | 1 |
Hamedani, F | 1 |
Mo, Z | 1 |
Cinar, B | 1 |
Amin, HM | 2 |
Alkan, S | 1 |
Sharma, SP | 1 |
Rahal, R | 1 |
Frick, M | 1 |
Romero, R | 1 |
Korn, JM | 1 |
Kridel, R | 1 |
Chan, FC | 1 |
Meissner, B | 1 |
Bhang, HE | 1 |
Ruddy, D | 1 |
Kauffmann, A | 1 |
Farsidjani, A | 1 |
Derti, A | 1 |
Rakiec, D | 1 |
Naylor, T | 1 |
Pfister, E | 1 |
Kovats, S | 1 |
Kim, S | 1 |
Dietze, K | 1 |
Dörken, B | 1 |
Steidl, C | 1 |
Tzankov, A | 1 |
Hummel, M | 1 |
Monahan, J | 1 |
Morrissey, MP | 1 |
Fritsch, C | 1 |
Sellers, WR | 1 |
Cooke, VG | 1 |
Gascoyne, RD | 1 |
Stegmeier, F | 1 |
Cameron, F | 1 |
Sanford, M | 1 |
Guha, M | 1 |
McDermott, J | 1 |
Jimeno, A | 1 |
Ma, J | 1 |
Cheng, S | 1 |
Zong, H | 1 |
Coleman, M | 1 |
Small, S | 1 |
Blecua, P | 1 |
Mathew, S | 1 |
Vijay, P | 1 |
Eng, K | 2 |
Ali, S | 1 |
Johnson, A | 1 |
Chang, B | 1 |
Ely, S | 1 |
Elemento, O | 2 |
Mason, CE | 1 |
Kamel, S | 1 |
Horton, L | 1 |
Ysebaert, L | 1 |
Levade, M | 1 |
Tan, S | 1 |
Cole-Sinclair, M | 1 |
Reynolds, J | 1 |
Filshie, R | 1 |
Schischka, S | 1 |
Khot, A | 1 |
Sandhu, S | 1 |
Keating, MJ | 2 |
Nandurkar, H | 1 |
Shah, N | 1 |
Hutchinson, C | 1 |
Bodo, J | 2 |
Sun, D | 1 |
Durkin, L | 2 |
Lin, J | 1 |
Smith, MR | 3 |
Hsi, ED | 2 |
Herrera, AF | 1 |
Marostica, E | 1 |
Loury, D | 1 |
de Trixhe, XW | 1 |
Vermeulen, A | 1 |
De Nicolao, G | 1 |
Byrd, JC | 1 |
Advani, R | 2 |
Poggesi, I | 1 |
Bernard, S | 2 |
Danglade, D | 1 |
Gardano, L | 1 |
Laguillier, C | 1 |
Lazarian, G | 1 |
Roger, C | 1 |
Marzec, J | 1 |
Gribben, J | 1 |
Cymbalista, F | 1 |
Varin-Blank, N | 1 |
Ledoux, D | 1 |
Baran-Marszak, F | 1 |
Sinha, G | 1 |
Rattu, MA | 1 |
Kim, SS | 1 |
McMullen, JR | 1 |
Boey, EJ | 1 |
Ooi, JY | 1 |
Mancebo, SE | 1 |
Smith, JR | 1 |
Intlekofer, AM | 1 |
Myskowski, PL | 1 |
Furtado, M | 1 |
Munneke, B | 1 |
Cheah, CY | 2 |
Chihara, D | 2 |
Fowler, NH | 1 |
Champlin, RE | 1 |
Dousset, C | 1 |
Brosseau, C | 1 |
Maïga, S | 1 |
Kim, ES | 1 |
Dhillon, S | 1 |
Herishanu, Y | 1 |
Katz, BZ | 1 |
Hagiwara, K | 2 |
Kunishima, S | 1 |
Iida, H | 2 |
Miyata, Y | 1 |
Naoe, T | 1 |
Nagai, H | 3 |
Kater, AP | 1 |
Kersten, MJ | 1 |
Shetty, S | 1 |
Kraus, J | 1 |
Kraus, M | 1 |
Liu, N | 1 |
Besse, L | 1 |
Bader, J | 1 |
Geurink, PP | 1 |
de Bruin, G | 1 |
Kisselev, AF | 1 |
Overkleeft, H | 1 |
Driessen, C | 1 |
Berglöf, A | 1 |
Hamasy, A | 1 |
Meinke, S | 1 |
Palma, M | 1 |
Krstic, A | 1 |
Månsson, R | 1 |
Kimby, E | 2 |
Österborg, A | 1 |
Smith, CI | 1 |
Goldwirt, L | 1 |
Amorim, S | 1 |
Brice, P | 1 |
Brière, J | 1 |
de Kerviler, E | 1 |
Mourah, S | 1 |
Sauvageon, H | 1 |
Sun, B | 1 |
Fiskus, W | 1 |
Rajapakshe, K | 1 |
Coarfa, C | 1 |
Devaraj, SG | 1 |
Saenz, DT | 1 |
Krieger, S | 1 |
Bradner, JE | 1 |
Bhalla, KN | 1 |
de Claro, RA | 1 |
McGinn, KM | 1 |
Verdun, N | 1 |
Lee, SL | 1 |
Chiu, HJ | 1 |
Saber, H | 1 |
Brower, ME | 1 |
Chang, CJ | 1 |
Pfuma, E | 1 |
Habtemariam, B | 1 |
Bullock, J | 1 |
Nie, L | 1 |
Chen, XH | 1 |
Lu, DR | 1 |
Al-Hakim, A | 1 |
Kane, RC | 1 |
Kaminskas, E | 1 |
Justice, R | 1 |
Farrell, AT | 1 |
Pazdur, R | 1 |
Gayko, U | 1 |
Fung, M | 1 |
Faust, E | 1 |
Price, S | 1 |
James, D | 1 |
Doyle, M | 1 |
Bari, S | 1 |
Zhuang, SH | 1 |
Smolewski, P | 1 |
Witkowska, M | 1 |
Tokunaga, T | 1 |
Lee, H | 1 |
Chuang, H | 1 |
Turturro, F | 1 |
Oki, Y | 1 |
DeLa Rosa, M | 1 |
Addison, A | 1 |
Young, KH | 1 |
Silva, RS | 1 |
Bothos, J | 1 |
Bandyopadhyay, N | 1 |
Rizo, A | 1 |
Tucker, DL | 2 |
Rule, SA | 2 |
Wagner-Johnston, N | 1 |
Iberri, D | 1 |
Spurgeon, S | 1 |
Kozin, E | 1 |
Noto, K | 1 |
Bloehdorn, J | 1 |
Portell, C | 1 |
Furman, RR | 1 |
Lambert Kuhn, E | 1 |
Levêque, D | 1 |
Lioure, B | 1 |
Gourieux, B | 1 |
Bilbault, P | 1 |
Ruella, M | 2 |
Kenderian, SS | 1 |
Shestova, O | 1 |
Fraietta, JA | 1 |
Qayyum, S | 1 |
Maus, MV | 1 |
Klichinsky, M | 1 |
Kawalekar, OU | 1 |
Milone, M | 1 |
Mato, A | 1 |
Kalos, M | 1 |
Gill, S | 1 |
Dougé, A | 1 |
Ravinet, A | 1 |
Bay, JO | 1 |
Tournilhac, O | 1 |
Guièze, R | 1 |
Lemal, R | 1 |
Kaur, V | 1 |
Swami, A | 1 |
Mouhayar, E | 1 |
Kim, P | 1 |
Saba, NS | 1 |
Liu, D | 1 |
Underbayev, C | 1 |
Behrend, D | 1 |
Weniger, MA | 1 |
Skarzynski, M | 1 |
Gyamfi, J | 1 |
Fontan, L | 1 |
Melnick, A | 1 |
Grant, C | 1 |
Roschewski, M | 1 |
Navarro, A | 1 |
Pittaluga, S | 1 |
Dunleavy, K | 1 |
Wilson, WH | 1 |
Naylor, G | 1 |
Kruger, A | 1 |
Hamilton, MS | 1 |
Wu, C | 1 |
de Miranda, NF | 1 |
Wasik, AM | 1 |
Mansouri, L | 1 |
Galazka, K | 1 |
Machaczka, M | 1 |
Peng, R | 1 |
Rosenquist, R | 1 |
Sander, B | 1 |
Pan-Hammarström, Q | 1 |
Maruyama, D | 1 |
Kitano, T | 1 |
Ishikawa, T | 1 |
Shibayama, H | 1 |
Choi, I | 1 |
Hatake, K | 1 |
Nishikori, M | 1 |
Kinoshita, T | 1 |
Matsuno, Y | 1 |
Takahara, S | 1 |
Mohanty, A | 1 |
Sandoval, N | 1 |
Das, M | 1 |
Pillai, R | 1 |
Marcucci, G | 1 |
Weisenburger, DD | 1 |
Rosen, ST | 1 |
Ngo, VN | 1 |
Jacobson, C | 1 |
Kopp, N | 1 |
Layer, JV | 1 |
Redd, RA | 1 |
Tschuri, S | 1 |
Haebe, S | 1 |
van Bodegom, D | 1 |
Bird, L | 1 |
Christie, AL | 1 |
Christodoulou, A | 1 |
Saur, A | 1 |
Tivey, T | 1 |
Zapf, S | 1 |
Bararia, D | 1 |
Zimber-Strobl, U | 1 |
Rodig, SJ | 1 |
Weigert, O | 1 |
Soubeyran, P | 1 |
González-Bonet, LG | 1 |
García-Boyero, R | 1 |
Gaona-Morales, J | 1 |
Epperla, N | 1 |
Cashen, AF | 1 |
Ahn, KW | 1 |
Oak, E | 1 |
Kanate, AS | 1 |
Calzada, O | 1 |
Farmer, L | 1 |
Tallarico, M | 1 |
Nabhan, C | 1 |
Costa, LJ | 1 |
Kenkre, VP | 1 |
Hari, PN | 1 |
Fenske, TS | 1 |
Compagno, M | 1 |
Pighi, C | 1 |
Cheong, TC | 1 |
Meng, FL | 1 |
Poggio, T | 1 |
Yeap, LS | 1 |
Karaca, E | 1 |
Blasco, RB | 1 |
Langellotto, F | 1 |
Ambrogio, C | 1 |
Voena, C | 1 |
Kasar, SN | 1 |
Wu, CJ | 1 |
Gostissa, M | 1 |
Alt, FW | 1 |
Chiarle, R | 1 |
Diamantopoulos, PT | 1 |
Psichogiou, M | 1 |
Pantazatou, A | 1 |
Zervakis, K | 1 |
Rougala, N | 1 |
Giannakopoulou, N | 1 |
Daikos, G | 1 |
Viniou, NA | 1 |
Hallek, M | 1 |
Staudt, L | 1 |
Christian, B | 1 |
Baiocchi, RA | 1 |
Dasmahapatra, G | 1 |
Patel, H | 1 |
Dent, P | 1 |
Fisher, RI | 1 |
Friedberg, J | 1 |
Grant, S | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Phase Ib Clinical Trial of Buparlisib and Ibrutinib in Mantle Cell Lymphoma, Follicular Lymphoma and Diffuse Large B Cell Lymphoma[NCT02756247] | Phase 1 | 37 participants (Actual) | Interventional | 2016-05-09 | Completed | ||
Multi-institution Phase I/Ib Study of Ibrutinib With ABT-199 in Relapsed/Refractory Mantle Cell Lymphoma[NCT02419560] | Phase 1 | 37 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
Phase 3 Study of Ibrutinib in Combination With Venetoclax in Subjects With Mantle Cell Lymphoma[NCT03112174] | Phase 3 | 352 participants (Actual) | Interventional | 2017-06-29 | Active, not recruiting | ||
A Phase II Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma: A Window Period for Bioimmunotherapy Before Chemotherapy[NCT02427620] | Phase 2 | 131 participants (Anticipated) | Interventional | 2015-06-03 | Active, not recruiting | ||
A Phase II Study of Ibrutinib Plus Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma or Elderly Patients With Newly Diagnosed MCL[NCT01880567] | Phase 2 | 113 participants (Actual) | Interventional | 2013-07-15 | Active, not recruiting | ||
Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of Mantle Cell Lymphoma[NCT02682641] | Phase 2 | 50 participants (Anticipated) | Interventional | 2016-05-18 | Active, not recruiting | ||
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma[NCT01776840] | Phase 3 | 523 participants (Actual) | Interventional | 2013-05-16 | Active, not recruiting | ||
A Drug-Drug Interaction Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Subjects With B Cell Malignancy[NCT03301207] | Phase 1 | 25 participants (Actual) | Interventional | 2017-10-20 | Completed | ||
A Phase 2 Study of ABT-199 in Combination With Ibrutinib in the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma (AIM Study)[NCT02471391] | Phase 2 | 37 participants (Actual) | Interventional | 2015-07-22 | Active, not recruiting | ||
A Phase I/II Trial of Obinutuzumab, ABT-199 (GDC-0199) Plus Ibrutinib in Relapsed / Refractory Mantle Cell Lymphoma Patients[NCT02558816] | Phase 1/Phase 2 | 48 participants (Actual) | Interventional | 2015-10-14 | Active, not recruiting | ||
A Phase 2, Multicenter, Randomized Open-Label Study To Determine the Efficacy of Lenalidomide (Revlimid®) Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma[NCT00875667] | Phase 2 | 254 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
A Multicenter, Observational Study to Evaluate the Effectiveness of Lenalidomide (Revlimid®) in Subjects With Mantle Cell Lymphoma Who Have Relapsed or Progressed After Treatment With Ibrutinib or Are Refractory or Intolerant to Ibrutinib.[NCT02341781] | 30 participants (Actual) | Observational | 2015-04-30 | Completed | |||
A Phase II Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma[NCT02460276] | Phase 2 | 50 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
Long-term Effect of Chronic Ibrutinib Therapy on Left Atrial Function[NCT03751410] | 40 participants (Actual) | Observational [Patient Registry] | 2018-12-01 | Completed | |||
A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of the Novel PI3k Delta Inhibitor TGR-1202 in Combination With Ibrutinib in Patients With Select B-Cell Malignancies[NCT02268851] | Phase 1 | 45 participants (Actual) | Interventional | 2014-11-30 | Active, not recruiting | ||
A Phase II Study of Palbociclib (PD-0332991) in Combination With Ibrutinib in Patients With Previously Treated Mantle Cell Lymphoma[NCT03478514] | Phase 2 | 39 participants (Actual) | Interventional | 2018-09-11 | Active, not recruiting | ||
A Phase I Trial of Ibrutinib Plus PD 0332991 (Palbociclib) in Patients With Previously Treated Mantle Cell Lymphoma[NCT02159755] | Phase 1 | 28 participants (Actual) | Interventional | 2014-05-20 | Active, not recruiting | ||
Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)[NCT03136497] | Phase 1 | 10 participants (Actual) | Interventional | 2017-09-05 | Active, not recruiting | ||
Combination Ibrutinib and Rituximab for the Treatment of Chronic Graft-Versus-Host Disease Following Allogeneic Stem Cell Transplant[NCT03689894] | Phase 1/Phase 2 | 2 participants (Actual) | Interventional | 2019-04-11 | Terminated (stopped due to Insufficient accrual) | ||
Multicenter Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Relapsed or Refractory Mantle Cell Lymphoma[NCT01236391] | Phase 2 | 115 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
Phase Ib Dose Finding Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (MCL)[NCT02446236] | Phase 1 | 27 participants (Actual) | Interventional | 2015-06-18 | Active, not recruiting | ||
A Phase I Study of Ibrutinib (PCI-32765) in Combination With Revlimid/Dexamethasone (Rd) in Relapsed/Refractory Multiple Myeloma[NCT03702725] | Phase 1 | 14 participants (Actual) | Interventional | 2019-08-29 | Active, not recruiting | ||
Randomized Phase II Study of Dose-Adjusted EPOCH-Rituximab-Bortezomib (EPOCH-R-B) Induction Followed by Bortezomib Maintenance Versus Observation in Untreated Mantle Cell Lymphoma With Microarray Profiling and Proteomics[NCT00114738] | Phase 2 | 53 participants (Actual) | Interventional | 2005-06-15 | Completed | ||
Efficacy and Safety of Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma:a Single-center, Open-label, Pragmatic Clinical Trial[NCT05020392] | Phase 3 | 24 participants (Anticipated) | Interventional | 2021-09-14 | Recruiting | ||
A Phase 1b/2 Fixed-dose Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia[NCT01105247] | Phase 1/Phase 2 | 133 participants (Actual) | Interventional | 2010-05-31 | Completed | ||
Phase I Dose-Escalation Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell Lymphoma[NCT00849654] | Phase 1 | 66 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
Treatment Patterns, Outcomes, and Patient-Reported Health-Related Quality of Life: A Prospective Disease Registry of Patients With Mantle Cell Lymphoma Treated With Novel Agents[NCT03816683] | 229 participants (Actual) | Observational | 2019-04-01 | Active, not recruiting | |||
A Randomized, Controlled, Open-Label, Multicenter Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, Versus Temsirolimus in Subjects With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy[NCT01646021] | Phase 3 | 280 participants (Actual) | Interventional | 2012-12-10 | Completed | ||
Bortezomib Combined With Fludarabine and Cytarabine for Mantle Cell Lymphoma Patients:a Single Arm, Open-labelled, Phase 2 Study[NCT03016988] | Phase 2 | 50 participants (Anticipated) | Interventional | 2017-01-31 | Not yet recruiting | ||
A Phase 2, Open Label Single Arm Study for Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis[NCT03529955] | Phase 2 | 8 participants (Actual) | Interventional | 2018-06-12 | Completed | ||
A Phase 2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)[NCT02169180] | Phase 2 | 16 participants (Actual) | Interventional | 2014-08-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Area under the concentration curve of ibrutinib during 24 hours after dosing at steady state was determined using PopPK modeling. (NCT01776840)
Timeframe: Day 2 of Cycles 1, 2 and 3 (each cycle was of 28 days)
Intervention | nanogram*hour per milliliter (ng*h/mL) (Mean) |
---|---|
Ibrutinib + BR (Treatment B) | 425 |
Complete response (CR) rate is defined as the percentage of participants who achieve CR (based on investigator assessment) on or prior to the initiation of subsequent anticancer therapy. Criteria for CR: disappearance of all evidence of disease; mass of any size permitted if positron emission tomography (PET) negative; regression to normal size on computed tomography (CT); spleen and liver: not palpable, nodules disappeared; bone marrow: infiltrate cleared on repeat biopsy. (NCT01776840)
Timeframe: Up to 97 months
Intervention | percentage of participants (Number) |
---|---|
Ibrutinib + BR (Treatment B) | 65.5 |
Placebo + BR (Treatment A) | 57.6 |
Duration of complete response (DoCR) was defined as the interval between the date of initial documentation of a CR and the date of first documented evidence of PD or death whichever occurs first, for participants who achieved CR. (NCT01776840)
Timeframe: Up to 97 months
Intervention | months (Median) |
---|---|
Ibrutinib + BR (Treatment B) | NA |
Placebo + BR (Treatment A) | 78.1 |
Duration of Response (DoR) was defined as the interval between the date of initial documentation of a response including PR and the date of first documented evidence of PD or death. (NCT01776840)
Timeframe: Up to 97 months
Intervention | months (Median) |
---|---|
Ibrutinib + BR (Treatment B) | 81 |
Placebo + BR (Treatment A) | 63.5 |
Maximum observed plasma concentration of ibrutinib was determined using PopPK modeling. (NCT01776840)
Timeframe: Day 2 of Cycles 1, 2 and 3 (each cycle was of 28 days)
Intervention | ng/mL (Mean) |
---|---|
Ibrutinib + BR (Treatment B) | 74.5 |
Minimal residual disease negative rate was defined as the percentage of participants with a best overall response of CR with MRD-negative disease status (that is, <5 mantle cell lymphoma [MCL] cell per 10,000 leukocytes for detection using the MRD assay), as assessed by flow cytometry of a bone marrow and/or peripheral blood sample. (NCT01776840)
Timeframe: Up to 97 months
Intervention | percentage of participants (Number) |
---|---|
Ibrutinib + BR (Treatment B) | 62.1 |
Placebo + BR (Treatment A) | 56.5 |
Minimum observed plasma concentration of ibrutinib was determined using PopPK modeling. (NCT01776840)
Timeframe: Day 2 of Cycles 1, 2 and 3 (each cycle was of 28 days)
Intervention | nanograms per milliliter (ng/mL) (Mean) |
---|---|
Ibrutinib + BR (Treatment B) | 3.90 |
Number of participants with TEAEs were reported. Treatment-emergent adverse events are defined as adverse events with onset or worsening on or after date of first dose of study treatment up to and including 30 days after date of last dose of study medication, or the initiation of subsequent anticancer therapy, whichever is earlier. (NCT01776840)
Timeframe: Up to 97 months
Intervention | Participants (Count of Participants) |
---|---|
Ibrutinib + BR (Treatment B) | 259 |
Placebo + BR (Treatment A) | 257 |
CL/F of Ibrutinib was determined using population pharmacokinetics (PopPK modeling). (NCT01776840)
Timeframe: Day 2 of Cycles 1, 2 and 3 (each cycle was of 28 days)
Intervention | liter per hour (L/h) (Mean) |
---|---|
Ibrutinib + BR (Treatment B) | 1123 |
Oral volume of distribution at steady state of ibrutinib was determined using PopPK modeling. (NCT01776840)
Timeframe: Day 2 of Cycles 1, 2 and 3 (each cycle was of 28 days)
Intervention | liter (Mean) |
---|---|
Ibrutinib + BR (Treatment B) | 7286 |
Overall survival is defined as the time from the date of randomization to the date of the participant's death. (NCT01776840)
Timeframe: Up to 97 months
Intervention | months (Median) |
---|---|
Ibrutinib + BR (Treatment B) | NA |
Placebo + BR (Treatment A) | NA |
Percentage of participants with overall response that is participants who achieved CR or PR was reported. Criteria for CR: disappearance of all evidence of disease; mass of any size permitted if PET negative; regression to normal size on CT; spleen and liver: not palpable, nodules disappeared; bone marrow: infiltrate cleared on repeat biopsy. Criteria for PR: greater than or equal to (>=) 50% decrease in sum of the diameter of all target lesions compared with baseline, in absence of new lesions or unequivocal progression of non-target lesions. (NCT01776840)
Timeframe: Up to 97 months
Intervention | percentage of participants (Number) |
---|---|
Ibrutinib + BR (Treatment B) | 89.7 |
Placebo + BR (Treatment A) | 88.5 |
Progression-free survival (PFS) is defined as the interval between the date of randomization to the date of disease progression (PD) or relapse from complete response (CR) or death, whichever is first reported. Disease assessments were based on the 2007 Revised Response Criteria for Malignant Lymphoma. PD is defined as any new lesion or increase by 50 percent (%) of previously involved sites from nadir (PD criteria: Appearance of new nodal lesion 1.5 centimeters [cm] in any axis, 50% increase in sum of product of diameters [SPD] of greater than [>] 1 node or 50% increase in longest diameter of previously identified node 1 cm in short axis). (NCT01776840)
Timeframe: Up to 97 months
Intervention | months (Median) |
---|---|
Ibrutinib + BR (Treatment B) | 80.6 |
Placebo + BR (Treatment A) | 52.9 |
Time to response was defined as the interval between the date of randomization and the date of initial documentation of a response. (NCT01776840)
Timeframe: Up to 97 months
Intervention | months (Median) |
---|---|
Ibrutinib + BR (Treatment B) | 2.79 |
Placebo + BR (Treatment A) | 2.79 |
"Time to worsening in the Lymphoma subscale of the FACT-Lym, defined as the interval from the date of randomization to the start date of worsening of participant symptoms. Worsening was defined by a 5-point decrease from baseline, death, or a missing assessment due to being too ill, whichever occurred first. FACT-Lym Lymphoma subscale contains 15 questions, scores from 0 to 4 for each question (higher the worse). Lymphoma subscale score is the total of reverse scores, range 0 to 60. Higher scores indicate a better quality of life." (NCT01776840)
Timeframe: Up to 97 months
Intervention | months (Median) |
---|---|
Ibrutinib + BR (Treatment B) | 17.4 |
Placebo + BR (Treatment A) | 22.2 |
Time-to-next treatment was measured from the date of randomization to the start date of any anti-mantle cell lymphoma (anti-MCL) treatment subsequent to the study treatment. (NCT01776840)
Timeframe: Up to 97 months
Intervention | months (Median) |
---|---|
Ibrutinib + BR (Treatment B) | NA |
Placebo + BR (Treatment A) | 92.0 |
Duration of response was defined as the time from when the first response of CR, CRu, or PR was first achieved until documented tumor progression, or until the participant died from any cause, whichever occurred first. Participants who did not progress or die at the time of analysis were censored at the last assessment date that the participant was known to be progression-free. Participants who received a new treatment without documented progression were censored at the last assessment date that the participant was known to be progression-free. (NCT00875667)
Timeframe: From date of randomization to the data cut-off date of 07 March 2014; median study duration was 70.7 weeks for the lenalidomide arm and 69.3 weeks for the investigators choice arm
Intervention | Weeks (Median) |
---|---|
Lenalidomide | 69.6 |
Investigators Choice | 45.1 |
Duration of response was defined as the time from when the first response of CR, CRu, or PR was first achieved until documented tumor progression, or until the participant died from any cause, whichever occurred first. Participants who did not progress or die at the time of analysis were censored at the last assessment date that the participant was known to be progression-free. Participants who received a new treatment without documented progression were censored at the last assessment date that the participant was known to be progression-free. (NCT00875667)
Timeframe: From date of randomization to the study discontinuation date of 09 October 2018; median study duration was 103.9 weeks for lenalidomide and 87.0 weeks for the investigator choice arm
Intervention | Weeks (Median) |
---|---|
Lenalidomide | 70.1 |
Investigators Choice | 91.7 |
Overall survival was defined as the time from randomization until death from any cause. Participants alive or lost to follow-up at the time of analysis were censored at the last date they were known to be alive. (NCT00875667)
Timeframe: From date of randomization to the data cut-off date of 07 March 2014; overall median follow-up was 93.9 weeks
Intervention | weeks (Median) |
---|---|
Lenalidomide | 121.0 |
Investigators Choice | 91.7 |
Overall survival was defined as the time from randomization until death from any cause. Participants alive or lost to follow-up at the time of analysis were censored at the last date they were known to be alive. (NCT00875667)
Timeframe: From randomization to progression of disease or death; up to the study discontinuation date of 09 October 2018; overall median follow-up time was 285 weeks
Intervention | weeks (Median) |
---|---|
Lenalidomide | 120.6 |
Investigators Choice | 91.7 |
PFS was defined as time of randomization to the first observation of disease progression or death due to any cause, whichever was first. If a participant had not progressed or died, PFS was censored at the time of last assessment when the participant was known not to have progressed. For participants who received other anti-lymphoma therapy with no evidence of progression, PFS was censored at time of last tumor assessment with no evidence of progression prior to the start of new anti-lymphoma treatment. (NCT00875667)
Timeframe: From randomization to progression of disease or death; up to data cut off date of 07 March 2014; overall median follow-up time was 93.9 weeks
Intervention | weeks (Median) |
---|---|
Lenalidomide | 37.6 |
Investigators Choice | 22.7 |
Kaplan Meier estimates of PFS were defined as the time from randomization to the first observation of disease progression or death due to any cause, whichever was first. If a participant had not progressed or died, PFS was censored at the time of last completed assessment when the participant was known not to have progressed. For participants who received other anti-lymphoma therapy with no evidence of progression, PFS was censored at time of last tumor assessment with no evidence of progression prior to the start of new anti-lymphoma treatment. (NCT00875667)
Timeframe: From randomization to progression of disease or death; up to study discontinuation of 09 October 2018; overall median follow-up time was 285 weeks
Intervention | weeks (Median) |
---|---|
Lenalidomide | 37.3 |
Investigators Choice | 23.6 |
Time to Response was defined as the time from first dose of study drug to the date of the first response (having at least a PR) and was calculated only for responding participants. ). Participants with progression at the time of analysis were censored at the first assessment date that the participant was known to have progressed. Participants with SD at the time of analysis were censored at the last assessment date that the participant was known to be progression-free. (NCT00875667)
Timeframe: From randomization of study drug to time of first documented PR or better response; up to data cut-off date of 07 March 2014; median treatment duration was 24.3 weeks for the lenalidomide arm and 13.1 weeks for the investigators choice arm
Intervention | Weeks (Median) |
---|---|
Lenalidomide | 18.7 |
Investigators Choice | NA |
Time to first response was defined as the time from first dose of study drug to the date of the first response (having at least a PR). Participants with progression at the time of analysis were censored at the first assessment date that the participant was known to have progressed. Participants with SD at the time of analysis were censored at the last assessment date that the subject was known to be progression-free. (NCT00875667)
Timeframe: From date of randomization to the study discontinuation date of 09 October 2018; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm
Intervention | Weeks (Median) |
---|---|
Lenalidomide | 23.9 |
Investigators Choice | 40.0 |
Time to progression (TTP) was defined as the time from randomization until objective tumor progression. Time to progression did not include deaths. Participants without progression at the time of analysis were censored at the last assessment date that the participant was known to be progression-free. Participants who received a new anti-lymphoma treatment without documented progression were censored at the last assessment date that the participant was known to be progression-free. (NCT00875667)
Timeframe: From date of randomization to the data cut-off date of 07 March 2014; median study duration was 70.7 weeks for the lenalidomide arm and 69.3 weeks for the investigators choice arm
Intervention | Weeks (Median) |
---|---|
Lenalidomide | 39.3 |
Investigators Choice | 24.7 |
Time to progression (TTP) was defined as the time from randomization until objective tumor progression. Time to progression did not include deaths. Participants without progression at the time of analysis were censored at the last assessment date that the participant was known to be progression-free. Participants who received a new anti-lymphoma treatment without documented progression were censored at the last assessment date that the participant was known to be progression-free. (NCT00875667)
Timeframe: From date of randomization to the study discontinuation date of 09 October 2018; median study duration was 103.9 weeks for lenalidomide and 87.0 weeks for the investigator choice arm
Intervention | Weeks (Median) |
---|---|
Lenalidomide | 39.3 |
Investigators Choice | 24.7 |
Time to treatment failure was defined as the time from the first dose of study drug to discontinuation of treatment for any reason, including disease progression assessed by the investigator, treatment toxicity, or death. Participants who were on-treatment or completed the treatment according to the protocol were censored at the last date of drug intake. (NCT00875667)
Timeframe: From the date of the first treatment to the data cut-off date of 07 March 2014; median treatment duration was 24.3 weeks for the lenalidomide arm and 13.1 weeks for the investigators choice arm
Intervention | weeks (Median) |
---|---|
Lenalidomide | 24.4 |
Investigators Choice | 17.9 |
Time to treatment failure was defined as the time from the first dose of study drug to discontinuation of treatment for any reason, including disease progression assessed by the investigator, treatment toxicity, or death. Participants who were on-treatment or completed the treatment according to the protocol were censored at the last date of drug intake. (NCT00875667)
Timeframe: From date of first dose of treatment to the study discontinuation date of 09 October 2018; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm
Intervention | weeks (Median) |
---|---|
Lenalidomide | 24.4 |
Investigators Choice | 17.9 |
The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Appetite Loss Domain to Treatment Scale was scored between 0 and 100, with a higher score representing worse symptomatic expression. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.
Intervention | units on a scale (Mean) |
---|---|
Lenalidomide | -4.8 |
Investigators Choice | -4.1 |
The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Cognitive Functioning Scale ranges from 0 to 100, with a high score indicating better functioning. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.
Intervention | units on a scale (Mean) |
---|---|
Lenalidomide | 3.2 |
Investigators Choice | 2.9 |
The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Constipation Scale was scored between 0 and 100, with a higher score representing worse symptomatic expression. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.
Intervention | units on a scale (Mean) |
---|---|
Lenalidomide | -0.3 |
Investigators Choice | -3.5 |
"The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact).~The EORTC QLQ-C30 Diarhoea Scale was scored between 0 and 100, with a high score indicating better functioning. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement." (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and time of discontinuation from treatment visit.Up to final data cut-0ff date of 07 March 2014
Intervention | units on a scale (Least Squares Mean) |
---|---|
Lenalidomide | -7.2 |
Investigators Choice | -5.8 |
The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Dyspnoea Domain to Treatment Scale was scored between 0 and 100, with a higher score representing worse symptomatic expression. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.
Intervention | units on a scale (Mean) |
---|---|
Lenalidomide | -7.3 |
Investigators Choice | -5.8 |
The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Emotional Functioning Scale ranges from 0 to 100, with a high score indicating better functioning. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.
Intervention | units on a scale (Mean) |
---|---|
Lenalidomide | 6.9 |
Investigators Choice | 3.7 |
The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Fatigue Scale was scored between 0 and 100, with a higher score representing worse symptomatic expression. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.
Intervention | units on a scale (Mean) |
---|---|
Lenalidomide | -4.9 |
Investigators Choice | -2.9 |
The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Financial Problems Domain Scale was scored between 0 and 100, with a higher score representing worse symptomatic expression. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.
Intervention | units on a scale (Mean) |
---|---|
Lenalidomide | -10.9 |
Investigators Choice | -2.3 |
The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Global Health Status / QoL Domain to Treatment Scale was scored between 0 and 100, with a higher score representing a higher quality of life. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.
Intervention | units on a scale (Mean) |
---|---|
Lenalidomide | 4.6 |
Investigators Choice | 5.6 |
The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Insomnia Scale was scored between 0 and 100, with a high score representing worse symptomatic expression. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.
Intervention | units on a scale (Mean) |
---|---|
Lenalidomide | -12.8 |
Investigators Choice | -7.6 |
The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Nausea and Vomiting Scale was scored between 0 and 100, with a high score representing worse symptomatic expression. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.
Intervention | units on a scale (Mean) |
---|---|
Lenalidomide | -2.3 |
Investigators Choice | -0.6 |
The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Pain Scale was scored between 0 and 100, with a higher score representing worse symptomatic expression. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and time of discontinuation from treatment visit.Up to final data cut-0ff date of 07 March 2014
Intervention | units on a scale (Mean) |
---|---|
Lenalidomide | -5.8 |
Investigators Choice | -3.5 |
The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Physical Functioning Scale ranges from 0 to 100, with a high score indicating better functioning. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.
Intervention | units on a scale (Mean) |
---|---|
Lenalidomide | 3.4 |
Investigators Choice | -1.8 |
The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Role Functioning Scale ranges from 0 to 100, with a high score indicating better functioning. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.
Intervention | units on a scale (Mean) |
---|---|
Lenalidomide | 3.1 |
Investigators Choice | 5.0 |
The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Social Functioning Scale ranges from 0 to 100, with a high score indicating better functioning. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.
Intervention | units on a scale (Mean) |
---|---|
Lenalidomide | 5.1 |
Investigators Choice | 3.8 |
Overall Response Rate (ORR) was defined as the percentage of participants whose best response was Complete Response (CR), Complete Response unconfirmed (CRu) or Partial Response (PR). Participants who discontinued before any response had been observed or changed to other anti-lymphoma treatments before response had been observed, were considered as non-responders. Tumor Response was assessed by a modification of the International Lymphoma Workshop Response Criteria, IWRC, Cheson, 1999; CR is defined as the disappearance of all clinical and radiographic evidence of disease; CRu is defined as a CR, with a 1) residual lymph node mass >1.5 cm that has decreased by 75% in the sum of the product of the diameters (SPD). Individual nodes previously confluent decreased by more than 75% in the SPD compared with original mass; 2) indeterminate bone marrow; PR = is defined ≥50% decrease in 6 largest nodes or nodal masses. (NCT00875667)
Timeframe: From date of randomization to the data cut-off date of 07 March 2014; median treatment duration was 24.3 weeks for the lenalidomide arm and 13.1 weeks for the investigators choice arm
Intervention | Percentage of Participants (Number) |
---|---|
Lenalidomide | 40.0 |
Investigators Choice | 10.7 |
Overall Response Rate (ORR) was defined as the percentage of participants whose best response was Complete Response, Complete Response unconfirmed or Partial Response. Participants who had discontinued before any response has been observed or changed to other anti-lymphoma treatments before response had been observed, were considered as non-responders. Tumor Response was assessed by a modification of the International Lymphoma Workshop Response Criteria, IWRC, Cheson, 1999; CR is defined as the disappearance of all clinical and radiographic evidence of disease; CRu is defined as a CR, with a 1) residual lymph node mass >1.5 cm that has decreased by 75% in the sum of the product of the diameters (SPD). Individual nodes previously confluent decreased by more than 75% in the SPD compared with original mass; 2) indeterminate bone marrow; PR = is defined ≥50% decrease in 6 largest nodes or nodal masses. (NCT00875667)
Timeframe: From date of randomization to the study discontinuation date of 09 October 2018; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm
Intervention | Percentage of Participants (Number) |
---|---|
Lenalidomide | 45.9 |
Investigators Choice | 22.6 |
Tumor control rate was defined as the percentage of participants with a complete response (CR), unconfirmed complete response (CRu), partial response (PR) and stable disease (SD). Tumor Response was assessed by a modification of the International Lymphoma Workshop Response Criteria, IWRC, Cheson, 1999); CR is defined as the disappearance of all clinical and radiographic evidence of disease; CRu is defined as a CR, with a 1) residual lymph node mass >1.5 cm that has decreased by 75% in the sum of the product of the diameters (SPD). Individual nodes previously confluent decreased by more than 75% in the SPD compared with original mass; 2) indeterminate bone marrow; PR = is defined ≥50% decrease in 6 largest nodes or nodal masses. Stable disease (SD) is defined as less than a PR (see above) but is not progressive disease or relapsed disease. (NCT00875667)
Timeframe: From date of randomization to the data cut-off date of 07 March 2014; median treatment duration was 24.3 weeks for the lenalidomide arm and 13.1 weeks for the investigators choice arm
Intervention | Percentage of Participants (Number) |
---|---|
Lenalidomide | 69.4 |
Investigators Choice | 63.1 |
Tumor control rate was defined as the percentage of participants with a complete response (CR), unconfirmed complete response (CRu), partial response (PR) and stable disease (SD). Tumor Response was assessed by a modification of the International Lymphoma Workshop Response Criteria, IWRC, Cheson, 1999); CR is defined as the disappearance of all clinical and radiographic evidence of disease; CRu is defined as a CR, with a 1) residual lymph node mass >1.5 cm that has decreased by 75% in the sum of the product of the diameters (SPD). Individual nodes previously confluent decreased by more than 75% in the SPD compared with original mass; 2) indeterminate bone marrow; PR = is defined ≥50% decrease in 6 largest nodes or nodal masses. Stable disease (SD) is defined as less than a PR (see above) but is not progressive disease or relapsed disease. (NCT00875667)
Timeframe: From date of randomization to the discontinuation date of 09 October 2018; median treatment duration was 24.3 weeks for the lenalidomide arm and 13.1 weeks for the investigators choice arm
Intervention | Percentage of participants (Number) |
---|---|
Lenalidomide | 70.0 |
Investigators Choice | 65.5 |
The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Appetite Loss Domain was scored between 0 and 100, with a higher score representing worse symptomatic expression. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.
Intervention | units on a scale (Mean) | |||||
---|---|---|---|---|---|---|
Baseline | Change from Baseline to Cycle 3 Day 1 | Change from Baseline to Cycle 5 Day 1 | Change from Baseline to Cycle 7 Day 1 | Change from Baseline to Cycle 9 Day 1 | Change from Baseline to Treatment Discontinuation | |
Investigators Choice | 16.2 | -0.8 | 5.1 | -12.5 | -11.1 | 5.4 |
Lenalidomide | 18.1 | 2.5 | 1.9 | -2.3 | -4.3 | 4.8 |
The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Cognitive Functioning Domain ranges from 0 to 100, with a high score indicating better functioning. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.
Intervention | units on a scale (Mean) | |||||
---|---|---|---|---|---|---|
Baseline | Change from Baseline to Cycle 3 Day 1 | Change from Baseline to Cycle 5 Day 1 | Change from Baseline to Cycle 7 Day 1 | Change from Baseline to Cycle 9 Day 1 | Change from Baseline to Treatment Discontinuation | |
Investigators Choice | 83.6 | -2.3 | 1.3 | 4.2 | 5.6 | -2.3 |
Lenalidomide | 84.6 | 0.0 | -1.9 | -3.2 | -2.5 | -5.1 |
The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Constipation Domain was scored between 0 and 100, with a high score representing worse symptomatic expression. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.
Intervention | units on a scale (Mean) | |||||
---|---|---|---|---|---|---|
Baseline | Change from Baseline to Cycle 3 Day 1 | Change from Baseline to Cycle 5 Day 1 | Change from Baseline to Cycle 7 Day 1 | Change from Baseline to Cycle 9 Day 1 | Change from Baseline to Treatment Discontinuation | |
Investigators Choice | 8.6 | -0.8 | 1.3 | 0.0 | 0.0 | 0.8 |
Lenalidomide | 12.5 | 6.3 | 4.2 | 3.5 | -0.7 | 10.2 |
The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Diarhoea Domain was scored between 0 and 100, with a higher score representing worse symptomatic expression. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.
Intervention | units on a scale (Mean) | |||||
---|---|---|---|---|---|---|
Baseline | Change from Baseline to Cycle 3 Day 1 | Change from Baseline to Cycle 5 Day 1 | Change from Baseline to Cycle 7 Day 1 | Change from Baseline to Cycle 9 Day 1 | Change from Baseline to Treatment Discontinuation | |
Investigators Choice | 12.6 | -3.1 | 1.3 | -4.2 | 0.0 | 0.0 |
Lenalidomide | 15.7 | -3.5 | -4.2 | 2.4 | -2.1 | 1.6 |
The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Dyspnoea Domain was scored between 0 and 100, with a high score representing worse symptomatic expression. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.
Intervention | units on a scale (Mean) | |||||
---|---|---|---|---|---|---|
Baseline | Change from Baseline to Cycle 3 Day 1 | Change from Baseline to Cycle 5 Day 1 | Change from Baseline to Cycle 7 Day 1 | Change from Baseline to Cycle 9 Day 1 | Change from Baseline to Treatment Discontinuation | |
Investigators Choice | 21.2 | -0.8 | 0.0 | 4.2 | 5.6 | 0.8 |
Lenalidomide | 26.5 | -1.6 | -1.4 | -2.9 | 1.4 | 6.0 |
The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Emotional Domain ranges from 0 to 100, with a high score indicating better functioning. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.
Intervention | units on a scale (Mean) | |||||
---|---|---|---|---|---|---|
Baseline | Change from Baseline to Cycle 3 Day 1 | Change from Baseline to Cycle 5 Day 1 | Change from Baseline to Cycle 7 Day 1 | Change from Baseline to Cycle 9 Day 1 | Change from Baseline to Treatment Discontinuation | |
Investigators Choice | 78.5 | 1.3 | 1.3 | -3.1 | 1.4 | -1.5 |
Lenalidomide | 73.7 | 3.4 | 3.6 | 8.1 | 4.5 | -1.3 |
The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Fatigue Domain was scored between 0 and 100, with a higher score representing worse symptomatic expression. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.
Intervention | units on a scale (Mean) | |||||
---|---|---|---|---|---|---|
Baseline | Change from Baseline to Cycle 3 Day 1 | Change from Baseline to Cycle 5 Day 1 | Change from Baseline to Cycle 7 Day 1 | Change from Baseline to Cycle 9 Day 1 | Change from Baseline to Treatment Discontinuation | |
Investigators Choice | 39.2 | 2.1 | 3.4 | -6.9 | -7.4 | 2.6 |
Lenalidomide | 40.2 | 0.1 | -3.2 | -1.0 | -3.9 | 5.2 |
The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Financial Problems Domain was scored between 0 and 100, with a higher score representing worse symptomatic expression. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.
Intervention | units on a scale (Mean) | |||||
---|---|---|---|---|---|---|
Baseline | Change from Baseline to Cycle 3 Day 1 | Change from Baseline to Cycle 5 Day 1 | Change from Baseline to Cycle 7 Day 1 | Change from Baseline to Cycle 9 Day 1 | Change from Baseline to Treatment Discontinuation | |
Investigators Choice | 10.8 | -0.8 | -3.8 | -4.2 | -5.6 | 1.6 |
Lenalidomide | 19.5 | -7.0 | -7.0 | -2.9 | -9.2 | -4.3 |
The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Global Health Status / QoL Domain was scored between 0 and 100, with a higher score representing a higher quality of life. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.
Intervention | units on a scale (Mean) | |||||
---|---|---|---|---|---|---|
Baseline | Change from Baseline to Cycle 3 Day 1 | Change from Baseline to Cycle 5 Day 1 | Change from Baseline to Cycle 7 Day 1 | Change from Baseline to Cycle 9 Day 1 | Change from Baseline to Treatment Discontinuation | |
Investigators Choice | 58.4 | 2.3 | 3.2 | 7.3 | 8.3 | -1.0 |
Lenalidomide | 59.0 | -3.4 | -0.7 | 1.0 | 4.3 | -5.8 |
The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Insomnia Domain was scored between 0 and 100, with a higher score representing worse symptomatic expression. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.
Intervention | units on a scale (Mean) | |||||
---|---|---|---|---|---|---|
Baseline | Change from Baseline to Cycle 3 Day 1 | Change from Baseline to Cycle 5 Day 1 | Change from Baseline to Cycle 7 Day 1 | Change from Baseline to Cycle 9 Day 1 | Change from Baseline to Treatment Discontinuation | |
Investigators Choice | 25.7 | -4.7 | -6.4 | -16.7 | -16.7 | 0.8 |
Lenalidomide | 29.4 | -7.6 | -5.2 | -1.8 | -7.1 | -3.2 |
The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Nausea and Vomiting Domain was scored between 0 and 100, with a higher score representing worse symptomatic expression. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.
Intervention | units on a scale (Mean) | |||||
---|---|---|---|---|---|---|
Baseline | Change from Baseline to Cycle 3 Day 1 | Change from Baseline to Cycle 5 Day 1 | Change from Baseline to Cycle 7 Day 1 | Change from Baseline to Cycle 9 Day 1 | Change from Baseline to Treatment Discontinuation | |
Investigators Choice | 3.8 | 0.4 | 5.8 | 2.1 | 2.8 | 6.6 |
Lenalidomide | 4.9 | 2.5 | 2.6 | 5.3 | -0.7 | 0.5 |
The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Pain Domain was scored between 0 and 100, with a higher score representing worse symptomatic expression. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.
Intervention | units on a scale (Mean) | |||||
---|---|---|---|---|---|---|
Baseline | Cycle 3 Day 1 | Cycle 5 Day 1 | Cycle 7 Day 1 | Cycle 9 Day 1 | Treatment Discontinuation | |
Investigators Choice | 13.7 | -1.2 | -2.6 | 0.0 | -2.8 | 3.5 |
Lenalidomide | 22.6 | -2.2 | -0.2 | 3.2 | -3.2 | 4.6 |
The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Physical Functioning Scale ranges from 0 to 100, with a high score indicating better functioning. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.
Intervention | units on a scale (Mean) | |||||
---|---|---|---|---|---|---|
Baseline | Change from Baseline to Cycle 3 Day 1 | Change from Baseline to Cycle 5 Day 1 | Change from Baseline to Cycle 7 Day 1 | Change from Baseline to Cycle 9 Day 1 | Change from Baseline to Treatment Discontinuation | |
Investigators Choice | 78.9 | -3.7 | -2.1 | 4.2 | 11.1 | -5.1 |
Lenalidomide | 71.8 | -0.5 | 1.6 | 2.4 | 2.8 | -5.6 |
The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Role Functioning Scale ranges from 0 to 100, with a high score indicating better functioning. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.
Intervention | units on a scale (Mean) | |||||
---|---|---|---|---|---|---|
Baseline | Change from Baseline to Cycle 3 Day 1 | Change from Baseline to Cycle 5 Day 1 | Change from Baseline to Cycle 7 Day 1 | Change from Baseline to Cycle 9 Day 1 | Change from Baseline to Treatment Discontinuation | |
Investigators Choice | 73.9 | 3.5 | -6.4 | 0.0 | 13.9 | -4.3 |
Lenalidomide | 71.5 | -4.8 | 1.4 | 0.3 | 1.8 | -9.1 |
The EORTC-QLQ-C30 is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Social Functioning Domain ranges from 0 to 100, with a high score indicating better functioning. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT00875667)
Timeframe: Baseline known as screening visit, after cycle 2 (C3D1), after Cycle 4 (C5D1), after Cycle 6, (C7D1), after Cycle 8, (C9D1) and at discontinuation; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigator choice arm.
Intervention | units on a scale (Mean) | |||||
---|---|---|---|---|---|---|
Baseline | Change from Baseline to Cycle 3 Day 1 | Change from Baseline to Cycle 5 Day 1 | Change from Baseline to Cycle 7 Day 1 | Change from Baseline to Cycle 9 Day 1 | Change from Baseline to Treatment Discontinuation | |
Investigators Choice | 78.4 | -1.2 | -4.5 | 2.1 | 0.0 | -2.7 |
Lenalidomide | 74.9 | -1.0 | 1.6 | -1.5 | 4.3 | -5.1 |
Adverse events were assessed using National Cancer Institute, Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 3: according to the following scale: Grade 1 = Mild Adverse Event (AE), Grade 2 = Moderate AE, Grade 3 = Severe and Undesirable AE, Grade 4 = Life-threatening or Disabling AE, and Grade 5 = Death; Serious AEs (SAEs) are those that resulted in death, were life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly, or resulted in an important medical event that may have jeopardized the patient or required medical or surgical intervention to prevent one of the outcomes listed above. after the first dose of study drug and within 28 days after the last dose. A Treatment Emergent Adverse event (TEAE) is defined as any AE occurring or worsening on or after the first dose of study drug and within 28 days after the last dose of study drug. (NCT00875667)
Timeframe: From the date of the first dose of study drug to 28 days after the last dose, up to the study discontinuation date of 09 October 2018; median treatment duration was 24.3 weeks for lenalidomide and 13.1 weeks for the investigators choice arm
Intervention | Participants (Count of Participants) | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Any TEAE | Any TEAE Grade 3 AE | Any TEAE Grade 4 AE | Any TEAE Grade 5 AE | Any TEAE Related to the IP | Any Grade 3 AE Related to IP | Any Grade 4 AE Related to IP | Any Grade 5 AE Related to IP | Any Serious Adverse Event (SAE) | Any SAE Related to IP | Any TEAE Leading to Stopping of IP | Any Treatment Related AE Leading to Stopping IP | TEAE Leading to Dose Reduction/Interruption | Related AE Leading to Dose Reduct/Interruption | TEAE Leading to Dose Reduction | Related AE Leading to Dose Reduction | TEAE Leading to Dose Interruption | Related AE Leading to Dose Interruption | |
Investigators Choice | 69 | 49 | 29 | 2 | 51 | 36 | 19 | 0 | 22 | 12 | 14 | 7 | 33 | 29 | 13 | 10 | 28 | 25 |
Lenalidomide | 159 | 126 | 56 | 15 | 141 | 106 | 46 | 0 | 75 | 38 | 31 | 18 | 114 | 103 | 72 | 69 | 110 | 98 |
To assess the safety of TGR1202 in combination with ibrutinib relapsed or refractory CLL or MCL. DLT is based on the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. DLT refers to toxicities experienced at any time during the study treatment, defined as Grade 4 anemia; Grade 4 neutropenia lasting >7 days (while receiving growth factor support); Grade 4 thrombocytopenia lasting > 7 days; Grade ≥3 febrile neutropenia; and Grade ≥3 thrombocytopenia with Grade >2 hemorrhage;Grade ≥ 3 non-hematologic toxicity unresponsive to standard supportive care measure with the exception of asymptomatic Grade ≥3 lab abnormalities that resolve to ≤ Grade 1 or baseline within 7 days;treatment delay of ≥14 days due to unresolved toxicity; and non-hematologic toxicity of Grade 2 (at any time during treatment) that, in the judgment of the Investigators, Study Chair, and the Medical Monitor, is dose-limiting. (NCT02268851)
Timeframe: Participants were assessed every week or more often as needed during Cycle 1 or more often for up to 28 days to assess Dose-limiting toxicities (DLTs) during Phase I
Intervention | Participants (Count of Participants) |
---|---|
CLL: Phase I Cohort 1 | 0 |
MCL: Phase 1 Cohort 1 | 0 |
CLL: Phase I Cohort 2 | 0 |
MCL: Phase I Cohort 2 | 0 |
CLL Phase I/IICohort 3 (RPD2) | 0 |
MCL Phase I/II Cohort 3 (RPD2) | 0 |
Response rate of clinically significant GVHD will be assessed using NIH criteria (from 2014 NIH Consensus Development Project). (NCT03689894)
Timeframe: 6 weeks, 3 months, and 6 months after initiation of treatment
Intervention | Participants (Count of Participants) |
---|---|
Ibrutinib Plus Rituximab | 0 |
Mean change from baseline to Cycle 5 in the European Organisation for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30) Global Health Status Score according to EORTC QLQ-C30 Scoring Manual (3rd Edition, 2001). For global health status, positive changes indicated better health status or functioning, and negative changes indicated worsening of health status or functioning. Scale scores range from 0 to 100. A change in 5 to 10 points in either direction represents a small change; 10 to 20 points represents a moderate change and greater than 20 points represents a large change. (NCT01236391)
Timeframe: From Baseline to Cycle 5 (Week 20)
Intervention | scores on a scale (Mean) |
---|---|
EORTC QLQ-C30 | 0.6 |
Number of participants who had experienced at least one treatment emergent AE (NCT01236391)
Timeframe: From first dose of PCI-32765 to within 30 days of last dose for each participant or until study closure
Intervention | participants (Number) |
---|---|
PCI-32765 | 111 |
Area under the plasma concentration-time curve using data collected at 0, 1, 2, 4, 6-8, and 24 hours post dose (AUC0-24h) (NCT01236391)
Timeframe: Performed During the First Month of Receiving PCI-32765
Intervention | AUC0-24h (ng*h/mL) (Mean) |
---|---|
PCI-32765 - Day 8 | 953 |
PCI-45227 (Metabolite)- Day 8 | 1263 |
The primary endpoint of the study was overall response rate (ORR), defined as the proportion of participants who achieved a best overall response of complete response (CR) or partial response (PR), according to the revised International Working Group Criteria for non-Hodgkin's lymphoma (Cheson et al, 2007), as assessed by the investigator. CR is a complete disappearance of all disease, no new lesions, lymph nodes must have regressed and be PET negative, spleen and liver should not be palpable and without nodules, and bone marrow must be negative. PR is a >/= 50% decrease in the sum of the product of diameters of the target lesions, and >/= 50% decrease of splenic and hepatic nodules from baseline, no new lesions and no increase in the size of liver, spleen or non-target lesions. (NCT01236391)
Timeframe: The median follow-up time on study for all treated participants is 15.3 (range 1.9 - 22.3) months
Intervention | percentage of participants with response (Number) |
---|---|
PCI-32765 | 67.6 |
Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT00114738)
Timeframe: Date treatment consent signed to date off study, approximately 143 months and 7 days
Intervention | Participants (Count of Participants) |
---|---|
EPOCH-R+Bortezomib | 53 |
Overall Survival is the time between the first day of treatment to the day of death. The primary evaluation will be a Kaplan-Meier analysis with a two tailed log rank test. (NCT00114738)
Timeframe: up to 9.9 years
Intervention | Months (Median) |
---|---|
EPOCH-R+Bortezomib | 80.4 |
Time interval from start of treatment to documented evidence of disease progression. Progression is defined by at least one of the following: ≥50% increase in the sum of the products of at least two lymph nodes, appearance of new lymph nodes, ≥50% increase in the size of the liver and/or spleen as determined by measurement below the respective costal margin, appearance of new palpable hepatomegaly or splenomegaly that was not previously present, and ≥50% increase in the absolute number of circulating lymphocytes. (NCT00114738)
Timeframe: up to 9.9 years
Intervention | Months (Median) |
---|---|
EPOCH-R+Bortezomib | 29.3 |
Overall Survival is the time between the first day of treatment to the day of death. The primary evaluation will be a Kaplan-Meier analysis with a two tailed log rank test. (NCT00114738)
Timeframe: up to 9.9 years
Intervention | Months (Median) |
---|---|
Bortezomib Maintenance | 78.6 |
Observation | 87.5 |
Not Randomized | 31.6 |
Time interval from start of treatment to documented evidence of disease progression. Progression is defined by at least one of the following: ≥50% increase in the sum of the products of at least two lymph nodes, appearance of new lymph nodes, ≥50% increase in the size of the liver and/or spleen as determined by measurement below the respective costal margin, appearance of new palpable hepatomegaly or splenomegaly that was not previously present, and ≥50% increase in the absolute number of circulating lymphocytes.The primary evaluation will be a Kaplan-Meier analysis with a two tailed log rank test. (NCT00114738)
Timeframe: up to 5 years
Intervention | Months (Median) |
---|---|
Bortezomib Maintenance | 27.2 |
Observation | 33.5 |
Not Randomized | 7.8 |
Clinical response is assessed by the response criteria for lymphomas and is defined as a fraction of patients who have a complete response (CR) or a complete response (CR) + partial response (PR). A complete response is disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy, and normalization of those biochemical abnormalities (e.g. lactate dehydrogenase) definitely assignable to the lymphoma. Partial response is ≥50% decreased in the sum of the products of the greatest diameters of 6 largest dominant nodes or nodal masses. No increase in size of nodes, liver or spleen and no new sites of disease. Progressive disease is defined by at least one of the following: ≥50% increase in the sum of the products of at least two lymph nodes appearance of new lymph nodes, ≥50% increase in the size of the liver and/or spleen, ≥50% increase in the absolute number of circulating lymphocytes. (NCT00114738)
Timeframe: up to 22 weeks after initiation of therapy
Intervention | Percentage of patients (Number) | ||||
---|---|---|---|---|---|
Overall Response (CR+PR) | Complete Response | Stable Disease | Progressive Disease | Not Evaluable | |
EPOCH-R+Bortezomib | 92.5 | 86.7 | 3.8 | 1.9 | 1.9 |
Geometric mean ratio (Fed/Fasted) for PCI-32765 AUClast. The data were collected at 0, 0.5, 1, 2, 4, 6, 24 h post-dose. The AUClast was calculated from 0 up to 24 hours post-dose. (NCT01105247)
Timeframe: Fed was assessed on either Day 8 or Day 15 and Fasted was assessed on the remaining day as cross-over design.
Intervention | (Number) |
---|---|
Food Effect Cohort | 1.65 |
Number of participants who had experienced at least one treatment emergent AEs. (NCT01105247)
Timeframe: From first dose to within 30 days of last dose of PCI-32765
Intervention | Participants (Number) |
---|---|
PCI-32765 | 116 |
Food Effect | 11 |
Response criteria are as outlined in the IWCLL 2008 criteria (Hallek 2008) and as assessed by investigator, e.g. response requires 50% reduction in lymph node size. (NCT01105247)
Timeframe: The median follow-up time for all treated patients are 21 month, range (0.7 month, 29 months).
Intervention | Percentage of Participants (Number) |
---|---|
Treatment Naive | 71 |
Relapsed/ Refractory | 75.3 |
Food Effect | 56.3 |
Criteria for progression are as outlined in the IWCLL 2008 criteria (Hallek 2008) and as assessed by investigator, e.g. progression defined as a 50% increase in lymph node size. (NCT01105247)
Timeframe: The median follow-up time for all treated patients are 21 month, range (0.7 month, 29 months).
Intervention | Percentage of Participants (Number) |
---|---|
Treatment Naive | 96.3 |
Relapsed/ Refractory | 73.6 |
Food- Effect | NA |
The AUC-ss is the area under the plasma concentration time curve observed during steady state. (NCT01646021)
Timeframe: Cycle 1 and 2 (Day 1): Predose, 1, 2, 4 hr. postdose; Cycle 3 (day 1): Predose (Each cycle is of 21 days)
Intervention | nanogram*hour per milliliter (ng*h/mL) (Mean) |
---|---|
Ibrutinib | 561.6 |
Duration of response (CR or PR), defined as the duration in days from the date of initial response to the date of first documented evidence of progressive disease (or relapse for participants who experience CR during the study) or death. The analysis was based on the investigator assessment. (NCT01646021)
Timeframe: Approximately up to 48 months
Intervention | Months (Median) |
---|---|
Ibrutinib | 23.1 |
Temsirolimus | 6.3 |
Extent of exposure is defined as the duration of the treatment administered during the study. Duration of exposure is calculated as the number of months between the start and end of treatment. (NCT01646021)
Timeframe: Approximately up to 46.8 months
Intervention | Months (Median) |
---|---|
Ibrutinib | 14.39 |
Temsirolimus | 3.02 |
Medical resource utilization data associated with medical encounters related to disease was reported for all participants throughout the study. (NCT01646021)
Timeframe: Approximately up to 28.2 months
Intervention | Emergency room visits (Mean) |
---|---|
Ibrutinib | 1.2 |
Temsirolimus | 1.2 |
Medical resource utilization data associated with medical encounters related to disease was reported for all participants throughout the study. (NCT01646021)
Timeframe: Approximately up to 28.2 months
Intervention | Hospitalizations (Mean) |
---|---|
Ibrutinib | 3.1 |
Temsirolimus | 2.8 |
An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. (NCT01646021)
Timeframe: Time from first dose of study drug until the last dose date + 30 days or the start of a subsequent anti-neoplastic therapy, whichever occur earlier (Approximately up to 4 years)
Intervention | Participants (Count of Participants) |
---|---|
Ibrutinib | 139 |
Temsirolimus | 138 |
Biomarker evaluations to identify markers altering BCR signaling or activate alternative signaling pathways and explore their association with response or resistance to ibrutinib. Next-generation sequencing at baseline identifies possible primary resistance mutations and those found only at progression are acquired mutations on therapy. (NCT01646021)
Timeframe: Approximately up to 28.2 months
Intervention | Participants (Number) |
---|---|
Ibrutinib | 61 |
Temsirolimus | 53 |
One -year survival rate, defined as the proportion of participants who were alive 1 year after randomization. (NCT01646021)
Timeframe: Month 12
Intervention | Proportion of participants (Number) |
---|---|
Ibrutinib | 0.68 |
Temsirolimus | 0.61 |
ORR is defined as the percentage of participants who achieved either CR or PR as best overall response based on the investigator assessment. CR is Disappearance of all target lesions while PR is greater than or equal to 30 % decrease in the sum of the longest diameter of target lesions and Overall Response (OR) is sum of CR and PR. (NCT01646021)
Timeframe: Approximately up to 48 months
Intervention | Percentage of participants (Number) |
---|---|
Ibrutinib | 77.0 |
Temsirolimus | 46.8 |
Overall survival (OS) was defined as the interval between the date of randomization and the date of death from any cause. (NCT01646021)
Timeframe: Approximately up to 48 months
Intervention | Months (Median) |
---|---|
Ibrutinib | 30.3 |
Temsirolimus | 23.5 |
PFS is defined as the duration in months from the date of randomization to the date of progression disease (PD) or relapse from complete response (CR) or death whichever was reported first and was assessed based on the investigator assessment. Revised Response Criteria for Malignant Lymphoma categorizes the response of the treatment of a patient's tumour to CR (the disappearance of all evidence of disease), Relapsed Disease or PD (Any new lesion or increase by greater than or equal to [>=] 50 percent [%] of previously involved sites from nadir). (NCT01646021)
Timeframe: Time from the date of randomization until the date of first documented evidence of progressive disease (or relapse for subjects who experience CR during the study) or death, whichever occurred first (approximately 48 months)
Intervention | Months (Median) |
---|---|
Ibrutinib | 15.6 |
Temsirolimus | 6.2 |
Progression-free survival 2 defined as the time interval between the date of randomization and date of event, defined as progressive disease as assessed by investigator that started after the next line of subsequent anti-neoplastic therapy (including cross-over to ibrutinib), death from any cause, or the start of the second subsequent anti-neoplastic therapy if no progressive disease was recorded after the first subsequent anti-neoplastic therapy. (NCT01646021)
Timeframe: Approximately up to 48 months
Intervention | Months (Median) |
---|---|
Ibrutinib | 26.2 |
Temsirolimus | 15.4 |
Time to response for participants with CR/PR, defined as the interval between the date of randomization and date of initial documentation of response. (NCT01646021)
Timeframe: Approximately up to 2.8 years
Intervention | Months (Median) |
---|---|
Ibrutinib | 2.15 |
Temsirolimus | 2.14 |
Time to worsening in the Lymphoma subscale of the FACT-Lym, defined as the interval from the date of randomization to the start date of worsening. Worsening was defined by a 5-point decrease from baseline. FACT-Lym Lymphoma subscale contains 15 questions, scores from 0 to 4 for each question (higher the worse). Lymphoma subscale score is the total of reverse scores, range 0 to 60. Higher scores indicate a better quality of life. (NCT01646021)
Timeframe: Approximately up to 48 months
Intervention | Weeks (Median) |
---|---|
Ibrutinib | NA |
Temsirolimus | 10.6 |
Time to next treatment was measured from the date of randomization to the start date of any anti-neoplastic treatment subsequent to study treatment. (NCT01646021)
Timeframe: Approximately up to 48 months
Intervention | Months (Median) |
---|---|
Ibrutinib | 31.8 |
Temsirolimus | 11.6 |
Medical resource utilization data associated with medical encounters related to disease was reported for all participants throughout the study. (NCT01646021)
Timeframe: Approximately up to 28.2 months
Intervention | Days (Mean) | |
---|---|---|
Mean days of hospitalization | Mean days of emergency room visits | |
Ibrutinib | 19.7 | 1.8 |
Temsirolimus | 20.3 | 1.6 |
The EQ-5D is a participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression, using 5 levels (1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and possible total score range -0.594 to 1; higher score indicates a better health state. (NCT01646021)
Timeframe: Baseline, Cycle 2, 3, 4, 5, 6, 7, 8, 11, 14, 17, 20, 28, 36 and End of treatment (approximately up to 23 months)
Intervention | Units on scale (Mean) | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Baseline | Change at Cycle 2 | Change at Cycle 3 | Change at Cycle 4 | Change at Cycle 5 | Change at Cycle 6 | Change at Cycle 7 | Change at Cycle 8 | Change at Cycle 11 | Change at Cycle 14 | Change at Cycle 17 | Change at Cycle 20 | Change at Cycle 28 | Change at Cycle 36 | Change at End of treatment | |
Ibrutinib | 0.7 | 0.0 | 0.1 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.1 | 0.0 | 0.0 |
Temsirolimus | 0.7 | 0.0 | -0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | -0.1 | -0.1 |
"MMT-8 (Manual Muscle Testing-8) score is a validated tool to assess muscle strength. Calculate the mean change in MMT-8 score at 3 and 6 month(s) compared to baseline in patients with muscle disease.~Units: Units on a scale. Scale goes from 0-150. 150 is perfect strength." (NCT03529955)
Timeframe: Data collected at 3 and 6 months after baseline visit
Intervention | score on a scale (Mean) |
---|---|
MMT-8 Score at 3 Months | 143.3 |
MMT-8 Score at 6 Months | 144.5 |
"Dermatology Life Quality Index (DLQI) is a validated tool to measure quality of life in patients with skin disease. Complete response is defined by a DLQI of zero at 3, and 6 months. Partial response is defined by a decrease of DLQI of at least 5 points at 3, and 6 months compared to baseline. Calculation is performed as the DLQI at 3, and 6 months minus the score at baseline. Missing data will be handled using the last observation carried forward approach (LOCF).~Units : Units on a scale from 0-30, higher scores represent worse outcome." (NCT03529955)
Timeframe: Data collected at 3 and 6 months after baseline visit
Intervention | score on a scale (Mean) |
---|---|
DLQI Score at 3 Months | 6.3 |
DLQI Score at 6 Months | 4.2 |
"The durability of response will be measured using the CDASI activity score at 6 months minus CDASI activity score at 3 months. Complete response durability is defined as zero or minus difference between CDASI activity score at 6 months and CDASI activity score at 3 months. Partial response durability is defined as >4 points difference between CDASI activity score at 6 months and CDASI activity score at 3 months. Missing data will be handled using the last observation carried forward approach (LOCF).~CDASI activity score: Units on a scale from 0-100. Higher scores represent worse outcome." (NCT03529955)
Timeframe: Data collected at 6 months compared to data collected at 3 months
Intervention | score on a scale (Mean) |
---|---|
CDASI Score at 3 Months | 16.9 |
CDASI Score at 6 Months | 14 |
"Cutaneous dermatomyositis disease area and severity index (CDASI) activity score is a validated tool to measure skin disease activity in dermatomyositis. The overall response rate (ORR) includes partial and complete responses. Complete response is defined by a CDASI activity score of zero. Partial response is defined by a decrease of CDASI activity score of at least 4 points. Calculation is performed as the CDASI activity score at 3 month(s) minus the score at baseline. Missing data will be handled using the last observation carried forward approach (LOCF).~CDASI activity score: Units on a scale from 0-100. Higher scores represent worse outcome." (NCT03529955)
Timeframe: Data collected at 3 months after baseline visit
Intervention | Participants (Count of Participants) |
---|---|
Dermatomyositis Patients With Refractory Cutaneous Disease | 7 |
"The proportion of participants experiencing adverse events and serious adverse events was measured over 7 months period (6 months during the study and 1 month follow up) using Common Terminology Criteria for Adverse Events (CTCAE) v5.0.~Grade refers to severity of the AE. The CTCAE displays Grades 1 to 5 with unique clinical descriptions of severity for each AE:~Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age- appropriate instrumental Activity of Daily Living (ADL) Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL Grade 4 Life-threatening consequences; urgent intervention indicated Grade 5 Death related to AE All adverse events subjects experienced were grade 1 or 2 which is mild to moderate in severity." (NCT03529955)
Timeframe: 7 months
Intervention | Participants (Count of Participants) | ||||||||
---|---|---|---|---|---|---|---|---|---|
Headache Grade 1-2 | Nausea Grade 1-2 | Diarrhea Grade 1-2 | Herpes Zoster Grade 1-2 | Influenza Grade 1-2 | Pneumonia Grade 1-2 | Acute sinusitis Grade 1-2 | Hypertension Grade 1-2 | Ocular pressure Grade 1-2 | |
Dermatomyositis Patients With Refractory Cutaneous Disease | 7 | 5 | 4 | 2 | 1 | 1 | 1 | 1 | 1 |
Skin biopsies from lesional skin will be performed before treatment with apremilast and after 3 months of treatment to assess changes in gene expression profiling and immunohistochemistry stain. Gene expression profiling will be analyzed using inferential statistics with a False Discovery Rate (FDR) of < 0.05. (NCT03529955)
Timeframe: Data collected at 3 months after baseline visit
Intervention | Change (Number) | |
---|---|---|
Down regulated genes | Up regulated genes | |
Skin Biopsy at 3 Months Into Apremilast Therapy for Gene Expression Profiling | 123 | 72 |
Skin Biopsy at Baseline for Gene Expression Profiling | 0 | 0 |
Skin biopsies from lesional skin will be performed before treatment with apremilast and after 3 months of treatment to assess changes in immunohistochemistry stain. (NCT03529955)
Timeframe: Data collected at 3 months after baseline visit
Intervention | Percentage of positive cell detection (Mean) | |
---|---|---|
STAT1 | STAT3 | |
Skin Biopsy at 3 Months Into Apremilast Therapy for IHC | 50.1 | 17.4 |
Skin Biopsy at Baseline for IHC | 96.2 | 44.3 |
39 reviews available for adenine and Lymphoma, Mantle-Cell
Article | Year |
---|---|
Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Humans; Lymphoma, Mantle | 2022 |
Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
Topics: Adenine; Antineoplastic Agents; Benzamides; Bortezomib; Humans; Lenalidomide; Lymphoma, Mantle-Cell; | 2019 |
The role of Bruton's tyrosine kinase inhibitors in the management of mantle cell lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Benzamides; Humans; Immunothera | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Benzamides; Clinical Trials a | 2021 |
Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Atrial Fibrillation; Drug Discovery; Graft vs Host Dis | 2017 |
Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: A case series and review of the literature.
Topics: Adenine; Aged; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Male; Piperidi | 2018 |
Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies.
Topics: Adenine; Antineoplastic Agents; Humans; Lymphoma, Mantle-Cell; Piperidines; Pyrazoles; Pyrimidines; | 2017 |
Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects.
Topics: Adenine; Drug Resistance, Neoplasm; Humans; Lymphoma, Mantle-Cell; Piperidines; Pyrazoles; Pyrimidin | 2018 |
Novel therapies for relapsed/refractory mantle cell lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Humans; Lymphoma, Mantle-Cell; | 2018 |
Use of acalabrutinib in patients with mantle cell lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Humans; Infection Control; Infections; Lym | 2018 |
Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: implications for design of clinical trials.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Bridged Bicyclo Compounds, Heterocyclic; Clinical Tria | 2018 |
Maintenance Therapy in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy P | 2018 |
Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies-A single institution experience and a review of literature.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Pi | 2019 |
Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Topics: Adenine; Adult; Antineoplastic Agents; Cost-Benefit Analysis; Humans; Lymphoma, Mantle-Cell; Piperid | 2019 |
Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; B-Lymphocytes; Benzamides; Drug | 2018 |
Lenalidomide for the treatment of mantle cell lymphoma.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; | 2019 |
Acalabrutinib for adults with mantle cell lymphoma.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Benzamides; Hum | 2019 |
Interrogating B cell signaling pathways: A quest for novel therapies for mantle cell lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Apoptosis; B-Lymphocytes; Humans; Lymphoma, Mantle-Cel | 2019 |
Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis.
Topics: Adenine; Atrial Fibrillation; Databases, Factual; Humans; Hypertension; Leukemia, Lymphocytic, Chron | 2019 |
Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma: review of current evidence and future directions.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antigens, CD20; Antineoplastic Agents; Antineoplastic | 2019 |
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765).
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Autoimmune Diseases; B-Lymphocytes; Drug Eval | 2013 |
Ibrutinib in chronic lymphocytic leukemia and B cell malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Disease-Free Survival; Humans; Leukemia, Lymphocytic, | 2014 |
Ibrutinib: first global approval.
Topics: Adenine; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular | 2014 |
Ibrutinib in B-cell Lymphomas.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Boronic Acids; Bortezomib; Clin | 2014 |
Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lympho | 2014 |
Ibrutinib for the treatment of mantle cell lymphoma.
Topics: Adenine; Antineoplastic Agents; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Lymp | 2014 |
A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Disease-Free Survival; Human | 2016 |
Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as To | 2015 |
Targets for Ibrutinib Beyond B Cell Malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Atrial Fibrillation; Humans; Leukemia, Lympho | 2015 |
[Ibrutinib: A new drug of B-cell malignancies].
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Chromosome Deletion; Genes, p53 | 2015 |
Ibrutinib in B lymphoid malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Clinical Trials as Top | 2015 |
Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies.
Topics: Adenine; Antineoplastic Agents; B-Lymphocytes; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph | 2015 |
Treatment options for mantle cell lymphoma.
Topics: Adenine; Antineoplastic Agents; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; | 2015 |
Mantle Cell Lymphoma.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2016 |
Ibrutinib for mantle cell lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Antineoplastic Combine | 2016 |
Ibrutinib (Imbruvica). Relapsed chronic lymphocytic leukaemia and mantle cell lymphoma: uncertain impact on survival.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, | 2016 |
Walking a tightrope: clinical use of ibrutinib in mantle cell lymphoma in the elderly.
Topics: Adenine; Aged; Aspirin; Diarrhea; Hemorrhage; Humans; Lymphoma, Mantle-Cell; Male; Neoplasm Staging; | 2016 |
Targeting of B-cell receptor signalling in B-cell malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Humans | 2017 |
33 trials available for adenine and Lymphoma, Mantle-Cell
Article | Year |
---|---|
Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring.
Topics: Adenine; Adult; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Cell-Free Nucleic Ac | 2022 |
Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma.
Topics: Adenine; Adult; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyc | 2022 |
Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study.
Topics: Adenine; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicycl | 2021 |
Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma.
Topics: Adenine; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bioma | 2022 |
Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma.
Topics: Adenine; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bioma | 2022 |
Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma.
Topics: Adenine; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bioma | 2022 |
Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma.
Topics: Adenine; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bioma | 2022 |
Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial.
Topics: Adenine; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Lymphoma, Mantle-Cell; | 2022 |
Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial.
Topics: Adenine; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxoru | 2022 |
A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma.
Topics: Adenine; Humans; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Piperidines; Pyrimidines; Quinaz | 2022 |
Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma.
Topics: Adenine; Adult; Arthralgia; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; M | 2022 |
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease P | 2022 |
Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial.
Topics: 3' Untranslated Regions; Adenine; Adult; Biological Factors; Humans; Lymphoma, Mantle-Cell; Neoplasm | 2022 |
A phase I study of carfilzomib in combination with ibrutinib for relapsed refractory mantle cell lymphoma.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Humans; Lymphoma, | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6.
Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Area Under Curve; Bupropion; Contrace | 2020 |
Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial.
Topics: Adenine; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemoth | 2021 |
Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Resist | 2017 |
Implementation of a Model-Based Design in a Phase Ib Study of Combined Targeted Agents.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Do | 2017 |
Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity.
Topics: Adaptor Proteins, Signal Transducing; Adenine; Coculture Techniques; Cytotoxicity, Immunologic; Dose | 2017 |
Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; | 2018 |
Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Follow-Up Studies; Humans; International Ag | 2018 |
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.
Topics: Adenine; Administration, Oral; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineo | 2018 |
Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties.
Topics: Adenine; Adult; Aged; Allografts; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoieti | 2019 |
Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL).
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Follow-Up Studies; Humans; Ki-67 Antigen; Lymphoma, Ma | 2018 |
Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2018 |
Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Heterocycl | 2019 |
Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: final analysis of phase I study.
Topics: Adenine; Asian People; Female; Follow-Up Studies; Humans; Japan; Leukemia, Lymphocytic, Chronic, B-C | 2019 |
A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Fol | 2019 |
A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Fol | 2019 |
A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Fol | 2019 |
A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Fol | 2019 |
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.
Topics: Adenine; Antigens, CD19; Antineoplastic Agents; B-Lymphocytes; Blotting, Western; CD5 Antigens; Cell | 2013 |
Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.
Topics: Adenine; Antigens, CD19; Antineoplastic Agents; B-Lymphocytes; Blotting, Western; CD5 Antigens; Cell | 2013 |
Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.
Topics: Adenine; Antigens, CD19; Antineoplastic Agents; B-Lymphocytes; Blotting, Western; CD5 Antigens; Cell | 2013 |
Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.
Topics: Adenine; Antigens, CD19; Antineoplastic Agents; B-Lymphocytes; Blotting, Western; CD5 Antigens; Cell | 2013 |
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; | 2015 |
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; | 2015 |
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; | 2015 |
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; | 2015 |
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; | 2015 |
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; | 2015 |
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; | 2015 |
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; | 2015 |
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; | 2015 |
Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillatio | 2016 |
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Kaplan-Meier Estimate; Lymp | 2016 |
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Kaplan-Meier Estimate; Lymp | 2016 |
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Kaplan-Meier Estimate; Lymp | 2016 |
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Kaplan-Meier Estimate; Lymp | 2016 |
Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma.
Topics: Adenine; Amino Acid Substitution; Apoptosis; Disease-Free Survival; Drug Resistance, Neoplasm; Femal | 2016 |
Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; | 2016 |
137 other studies available for adenine and Lymphoma, Mantle-Cell
Article | Year |
---|---|
miRNA-223-3p modulates ibrutinib resistance through regulation of the CHUK/Nf-κb signaling pathway in mantle cell lymphoma.
Topics: Adenine; Animals; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; I-kappa | 2021 |
Successful treatment of second-time CAR-T 19 therapy after failure of first-time CAR-T 19 and ibrutinib therapy in relapsed mantle cell lymphoma.
Topics: Adenine; Adult; Animals; Humans; Immunotherapy, Adoptive; Lymphoma, Mantle-Cell; Mice; Piperidines; | 2022 |
Dual targeting of PI3K and BCL-2 overcomes ibrutinib resistance in aggressive mantle cell lymphoma.
Topics: Adenine; Adult; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Lymphoma, Mantle-Cell; Phosphat | 2022 |
IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice.
Topics: Adenine; Adult; Humans; Lymphoma, Mantle-Cell; Middle Aged; Neoplasm Recurrence, Local; Piperidines; | 2022 |
SHINE a light: frontline ibrutinib for MCL.
Topics: Adenine; Humans; Lymphoma, Mantle-Cell; Piperidines | 2022 |
Outcomes for Recurrent Mantle Cell Lymphoma Post-Ibrutinib Therapy: A Retrospective Cohort Study from a Japanese Administrative Database.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; | 2022 |
Treatment of Mantle-Cell Lymphoma.
Topics: Adenine; Adult; Bendamustine Hydrochloride; Humans; Lymphoma, Mantle-Cell; Piperidines; Rituximab | 2022 |
Treatment of Mantle-Cell Lymphoma.
Topics: Adenine; Adult; Bendamustine Hydrochloride; Humans; Lymphoma, Mantle-Cell; Piperidines; Rituximab | 2022 |
Treatment of Mantle-Cell Lymphoma.
Topics: Adenine; Adult; Bendamustine Hydrochloride; Humans; Lymphoma, Mantle-Cell; Piperidines; Rituximab | 2022 |
Treatment of Mantle-Cell Lymphoma. Reply.
Topics: Adenine; Adult; Bendamustine Hydrochloride; Humans; Lymphoma, Mantle-Cell; Piperidines; Rituximab | 2022 |
[Five year experience in ibrutinib therapy for relapsed and refractory mantle cell lymphoma in real world Russian clinical practice].
Topics: Adenine; Aged; Clinical Trials as Topic; Humans; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; | 2021 |
A novel patient-derived 3D model recapitulates mantle cell lymphoma lymph node signaling, immune profile and in vivo ibrutinib responses.
Topics: Adenine; Adult; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Lymphoma, Mantle-Cell; Tumor Mi | 2023 |
Rare case of ocular adnexal relapse with mantle cell lymphoma treated with ibrutinib monotherapy.
Topics: Adenine; Aged; Antineoplastic Agents; Eye Neoplasms; Humans; Lymphoma, Mantle-Cell; Magnetic Resonan | 2019 |
Cutting Edge: ROR1/CD19 Receptor Complex Promotes Growth of Mantle Cell Lymphoma Cells Independently of the B Cell Receptor-BTK Signaling Pathway.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Cell Line, Tumor; Cell Proliferation; Dose-Response Re | 2019 |
Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real-world experience.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Age | 2019 |
Treatment patterns, adverse events, healthcare resource use and costs among commercially insured patients with mantle cell lymphoma in the United States.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; | 2019 |
Ibrutinib-Associated Reversible Cardiomyopathy.
Topics: Adenine; Aged; Cardiomyopathies; Humans; Lymphoma, Mantle-Cell; Male; Mesentery; Piperidines; Pyrazo | 2019 |
[Ibrutinib therapy for a blastoid variant mantle cell lymphoma patient with early extranodal relapse after autologous stem cell transplantation].
Topics: Adenine; Aged; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Male; Neoplas | 2019 |
Obinutuzumab and venetoclax induced complete remission in a patient with ibrutinib-resistant non-nodal leukemic mantle cell lymphoma.
Topics: Adenine; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Bridged Bicy | 2020 |
Ibrutinib treatment of mantle cell lymphoma complicated by progressive multifocal leukoencephalopathy
.
Topics: Adenine; Fatal Outcome; Female; Humans; Leukoencephalopathy, Progressive Multifocal; Lymphoma, Mantl | 2020 |
Mantle cell lymphoma turned SOX11 negative after ibrutinib: a report of two cases.
Topics: Adenine; Adult; Humans; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Piperidines; SOXC Transcription Fac | 2020 |
The 5-year follow-up of a real-world observational study of patients in the United Kingdom and Ireland receiving ibrutinib for relapsed/refractory mantle cell lymphoma.
Topics: Adenine; Aged; Aged, 80 and over; Disease-Free Survival; Female; Follow-Up Studies; Humans; Ireland; | 2021 |
Platelet function and bleeding in chronic lymphocytic leukemia and mantle cell lymphoma patients on ibrutinib.
Topics: Adenine; Adult; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Piperidines; | 2020 |
Transdifferentiation of lymphoma into sarcoma associated with profound reprogramming of the epigenome.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Cell Transdifferentiation; Cellular Reprogr | 2020 |
A case of "double hit" mantle cell lymphoma carrying CCND1 and MYC translocations relapsed/refractory to rituximab bendamustine cytarabine (R-BAC) and ibrutinib.
Topics: Abnormal Karyotype; Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydr | 2020 |
Life-threatening disseminated enterovirus infection during combined rituximab and ibrutinib maintenance treatment for mantle cell lymphoma: a case report.
Topics: Adenine; Adult; Antigens, CD20; Enterovirus Infections; Humans; Lymphoma, Mantle-Cell; Middle Aged; | 2020 |
Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy.
Topics: Adenine; Adult; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukocytes, Mononuclear; Lymphoma, | 2020 |
Rapid progression after ibrutinib discontinuation in a patient with mantle cell lymphoma who has severe coronavirus disease 2019 infection.
Topics: Adenine; Aged; Antineoplastic Agents; COVID-19; COVID-19 Drug Treatment; Follow-Up Studies; Humans; | 2021 |
Treatment patterns and outcomes among mantle cell lymphoma patients treated with ibrutinib in the United States: a retrospective electronic medical record database and chart review study.
Topics: Adenine; Aged; Aged, 80 and over; Electronic Health Records; Female; Humans; Lymphoma, Mantle-Cell; | 2021 |
Successful Long-Term Ibrutinib Treatment in a Hemodialysis Patient With Leukemic Nonnodal Mantle Cell Lymphoma.
Topics: Adenine; Aged; Diabetic Nephropathies; Humans; Lymphoma, Mantle-Cell; Male; Piperidines; Renal Dialy | 2021 |
[Mantle cell lymphoma with central nervous system relapse successfully treated with nasogastric-tube administration of ibrutinib].
Topics: Adenine; Aged; Central Nervous System; Central Nervous System Neoplasms; Humans; Lymphoma, Mantle-Ce | 2020 |
Does Ibrutinib impact outcomes of viral infection by SARS-CoV-2 in mantle cell lymphoma patients?
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Comorbidity; COVID-19; Humans; Lymphoma, Mantle- | 2021 |
Adverse Events and Economic Burden Among Patients Receiving Systemic Treatment for Mantle Cell Lymphoma: A Real-World Retrospective Cohort Study.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydro | 2021 |
Building on BTK inhibition in MCL.
Topics: Adenine; Adult; Antibodies, Monoclonal, Humanized; Bridged Bicyclo Compounds, Heterocyclic; Humans; | 2021 |
Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Combine | 2021 |
Real-world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis.
Topics: Adenine; Adult; Humans; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Piperidines; Republic of | 2021 |
Fatal splenic rupture after discontinuing treatment by ibrutinib and venetoclax in relapse/refractory mantle cell lymphoma.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocycl | 2021 |
Time-Resolved scRNA-Seq Tracks the Adaptation of a Sensitive MCL Cell Line to Ibrutinib Treatment.
Topics: Adenine; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; | 2021 |
How should we use ibrutinib in patients with mantle cell lymphoma?
Topics: Adenine; Adult; Humans; Lymphoma, Mantle-Cell; Piperidines; Pyrazoles; Pyrimidines | 2021 |
Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma.
Topics: Adenine; Animals; Cell Cycle Proteins; Cell Line, Tumor; Cyclin-Dependent Kinase 9; Drug Resistance, | 2021 |
CDKN1C-mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib.
Topics: Adenine; Animals; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Proliferation; Cyclin-Dependen | 2021 |
Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma.
Topics: Adenine; Adult; Aged; Combined Modality Therapy; Disease Progression; Drug Resistance, Neoplasm; Fem | 2021 |
Diagnostically challenging immunophenotypic shift in mantle cell lymphoma following ibrutinib and venetoclax therapy.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Comp | 2021 |
MCIR1: A patient-derived mantle cell lymphoma line for discovering new treatments for ibrutinib resistance.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; B-Lymphocytes; Cell Line, Tumor | 2021 |
Treatment Patterns Among Patients With Mantle Cell Lymphoma and Comparison of Healthcare Resource Utilization and Costs Among Relapsed/Refractory Patients Treated With Ibrutinib or Chemoimmunotherapy: A Real-world Retrospective Study.
Topics: Adenine; Adult; Aged; Female; Health Care Costs; Humans; Lymphoma, Mantle-Cell; Male; Patient Accept | 2021 |
B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Burkitt Lymphoma; Disease Models, Animal; Dru | 2017 |
Novel chemotherapy-free combination regimen for ibrutinib-resistant mantle cell lymphoma.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Drug Resis | 2018 |
Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma.
Topics: Adenine; Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Hu | 2017 |
Imbruvica
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Agents; Drug Industry; Humans; Le | 2017 |
Pulmonary Cryptococcus Presenting as a Solitary Pulmonary Nodule.
Topics: Adenine; Aged; Cryptococcosis; Humans; Immunocompromised Host; Lung Diseases, Fungal; Lymphoma, Mant | 2017 |
Sudden Flank Pain in a Patient Receiving Ibrutinib for Mantle Cell Lymphoma.
Topics: Acute Disease; Adenine; Female; Flank Pain; Hematoma; Humans; Kidney Diseases; Lymphoma, Mantle-Cell | 2018 |
Ibrutinib as salvage therapy in mantle cell lymphoma with central nervous system involvement in a pretreated unfit patient.
Topics: Adenine; Central Nervous System Neoplasms; Humans; Lymphoma, Mantle-Cell; Magnetic Resonance Imaging | 2018 |
Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment.
Topics: Adenine; Bone Marrow; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Female; Focal Adhe | 2018 |
Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004).
Topics: Adenine; Aged; Aged, 80 and over; Disease Progression; Female; Humans; Lenalidomide; Lymphoma, Mantl | 2017 |
NR4A1 inhibition synergizes with ibrutinib in killing mantle cell lymphoma cells.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Drug Synergism | 2017 |
Venetoclax as a single agent and in combination with PI3K-MTOR1/2 kinase inhibitors against ibrutinib sensitive and resistant mantle cell lymphoma.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Di | 2019 |
Promising efficacy of novel BTK inhibitor AC0010 in mantle cell lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Female; Humans; Lymphoma, Mantle-Cell; Mice; | 2018 |
Can we improve on ibrutinib in mantle cell lymphoma?
Topics: Adenine; Clinical Trials as Topic; Humans; Lymphoma, Mantle-Cell; Neoplasm Grading; Piperidines; Pyr | 2018 |
Combining Ibrutinib with Chk1 Inhibitors Synergistically Targets Mantle Cell Lymphoma Cell Lines.
Topics: Adenine; Cell Line, Tumor; Checkpoint Kinase 1; Humans; Lymphoma, Mantle-Cell; Piperidines; Protein | 2018 |
p110α Inhibition Overcomes Stromal Cell-Mediated Ibrutinib Resistance in Mantle Cell Lymphoma.
Topics: Adenine; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Line, Tumor; Class | 2018 |
Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Bacterial Infections; Electronic Health Records; Female; Hu | 2018 |
Impact of novel therapies for mantle cell lymphoma in the real world setting: a report from the UK's Haematological Malignancy Research Network (HMRN).
Topics: Adenine; Adult; Aged; Aged, 80 and over; Bendamustine Hydrochloride; Disease-Free Survival; Female; | 2018 |
Additive and synergistic inhibition of mantle cell lymphoma cell growth by combining olaparib with ibrutinib.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; | 2018 |
Targeted combination has synergy in MCL.
Topics: Adenine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Lymphoma, Mantle-Cell; Piperidines; Pyrazo | 2018 |
Integrated stress response and immune cell infiltration in an ibrutinib-refractory mantle cell lymphoma patient following ONC201 treatment.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Agents; Antineoplastic Combined C | 2019 |
Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma.
Topics: Adenine; Animals; Benzodioxoles; Cell Line, Tumor; Drug Resistance, Neoplasm; HSP90 Heat-Shock Prote | 2018 |
Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Disease-Free Survival; | 2018 |
Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma.
Topics: Adenine; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell | 2019 |
Precision therapies take aim at non-Hodgkin's lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Disease Models, Animal; Dogs; Drug Approval; | 2018 |
Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis.
Topics: Adenine; Clinical Trials as Topic; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Lymphoma, M | 2019 |
[Mantle cell lymphoma of the iris treated by ibrutinib].
Topics: Adenine; Aged; Antineoplastic Agents; Humans; Iris; Iris Neoplasms; Lymphoma, Mantle-Cell; Male; Pip | 2018 |
Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma.
Topics: Activating Transcription Factor 3; Adenine; bcl-X Protein; Bridged Bicyclo Compounds, Heterocyclic; | 2019 |
XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IκB.
Topics: Adenine; Apoptosis; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Down-Regulation; Drug Resist | 2018 |
Bruton tyrosine kinase degradation as a therapeutic strategy for cancer.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Cell Proliferation; Hu | 2019 |
Concurrent treatment with two B-cell receptor pathway inhibitors.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Piperidines; Protein | 2019 |
Aggressive Leukemic Non-Nodal Mantle Cell Lymphoma With P53 Gene Rearrangement/Mutation is Highly Responsive to Rituximab/Ibrutinib Combination Therapy.
Topics: Adenine; Antineoplastic Agents, Immunological; Gene Rearrangement; Humans; Lymphoma, Mantle-Cell; Ma | 2019 |
The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Bridge | 2019 |
Ibrutinib-associated Serositis in Mantle Cell Lymphoma.
Topics: Adenine; Aged; Antineoplastic Agents; Humans; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Pip | 2019 |
A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Biomarkers, Tumor; CD79 Antigen | 2019 |
Degradation of Bruton's tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Drug Resistance, Neoplasm; Humans; Lymphoma, Large B-C | 2019 |
Metabolic Detection of Bruton's Tyrosine Kinase Inhibition in Mantle Cell Lymphoma Cells.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzeneacetamides; Biomarkers, Tumor; Cell Line, Tumor | 2019 |
CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antigens, CD; Antigens, Differentiation, Myelomo | 2019 |
The Muddied Waters of Ibrutinib Therapy.
Topics: Adenine; Adult; Humans; Lymphoma, Mantle-Cell; Male; Neuroaspergillosis; Piperidines; Pyrazoles; Pyr | 2019 |
Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma.
Topics: Adenine; Animals; Cell Line, Tumor; DNA Copy Number Variations; Drug Resistance, Neoplasm; Exome Seq | 2019 |
Efficacy of the novel CDK7 inhibitor QS1189 in mantle cell lymphoma.
Topics: Adenine; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle; Cell Line, Tumo | 2019 |
Pharmacologic inhibition of the ubiquitin-activating enzyme induces ER stress and apoptosis in chronic lymphocytic leukemia and ibrutinib-resistant mantle cell lymphoma cells.
Topics: Adenine; Animals; Apoptosis; Biomarkers; Cell Line, Tumor; Drug Resistance, Neoplasm; Endoplasmic Re | 2019 |
Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma.
Topics: Adenine; Adult; Humans; Lymphoma, Mantle-Cell; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Py | 2020 |
Rates and Risk of Atrial Arrhythmias in Patients Treated With Ibrutinib Compared With Cytotoxic Chemotherapy.
Topics: Adenine; Age Factors; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibito | 2019 |
Ibrutinib: a strong candidate for the future of mantle cell lymphoma treatment.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Humans; Lymphoma, Mantle-Cell; Neoplasm Prote | 2013 |
Toward new treatments for mantle-cell lymphoma?
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Female; Humans; Lymphoma, Mantle-Cell; Male; Piperidin | 2013 |
Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Apoptosis; Cell Line; Cell Survival; Gene Expression; | 2013 |
Targeting the B-cell signalling pathway in CLL and MCL.
Topics: Adenine; B-Lymphocytes; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Piper | 2013 |
Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma.
Topics: Adenine; Baculoviral IAP Repeat-Containing 3 Protein; Base Sequence; Blotting, Western; CARD Signali | 2014 |
Ibrutinib approved for mantle cell lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Drug Approval; Humans; Lymphoma | 2014 |
Imbruvica--next big drug in B-cell cancer--approved by FDA.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Clinical Trials as Topic; Drug | 2014 |
Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Cell Cycle; Cell Death; Cell Pr | 2014 |
Ibrutinib approved for the treatment of mantle cell lymphoma.
Topics: Adenine; Drug Approval; Humans; Lymphoma, Mantle-Cell; Piperidines; Pyrazoles; Pyrimidines; United S | 2013 |
Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Amino Acid Substitution; Antineoplastic Agents; Cell C | 2014 |
A breakthrough in mantle cell lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Humans; Lymphoma, Mantle-Cell; Piperidines; Prot | 2014 |
Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation.
Topics: Adenine; Adenosine Diphosphate; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Platelets; Cel | 2015 |
Ibrutinib for the treatment of mantle cell lymphoma.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Apopto | 2015 |
Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Aminopyridines; Apoptosis; Bl | 2015 |
Overcoming mantle cell lymphoma's ibrutinib resistance.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2014 |
Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Animals, Newborn; Atrial Fibrillation; Gene E | 2014 |
Treatment response of cutaneous mantle cell lymphoma to ibrutinib and radiotherapy.
Topics: Adenine; Aged; Antineoplastic Agents; Fatal Outcome; Humans; Lymphoma, Mantle-Cell; Male; Piperidine | 2015 |
Ibrutinib-associated lymphocytosis corresponds to bone marrow involvement in mantle cell lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Bone Marrow; Humans; Lymphocytosis; Lymphoma, Mantle-C | 2015 |
Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; | 2015 |
Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Apoptosis; bcl-X Protein; Bridg | 2015 |
Cryoglobulins mimicking platelet recovery in a mantle cell lymphoma patient treated with chemoimmunotherapy.
Topics: Adenine; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochlo | 2015 |
The synergistic effect of BCR signaling inhibitors combined with an HDAC inhibitor on cell death in a mantle cell lymphoma cell line.
Topics: Adenine; Apoptosis; Caspases; Cell Line, Tumor; Cyclin D1; Drug Synergism; Histone Deacetylase Inhib | 2015 |
Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, | 2015 |
CCMCL1: a new model of aggressive mantle cell lymphoma.
Topics: Adenine; Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Proto | 2015 |
The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
Topics: Adenine; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neopla | 2015 |
Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse.
Topics: Adenine; Aged; Antineoplastic Agents; Central Nervous System Neoplasms; Female; Humans; Lymphoma, Ma | 2015 |
Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Azepines; Cell Cycle P | 2015 |
FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Clinical Trials as Topic; Drug Approval; Female; Humans; Leukemia, Lymphocytic, Chron | 2015 |
Synergistic Cytotoxicity of Bendamustine and the BTK Inhibitor in a Mantle Cell Lymphoma Cell Line.
Topics: Adenine; Bendamustine Hydrochloride; Cell Proliferation; Humans; Lymphoma, Mantle-Cell; Piperidines; | 2015 |
Ibrutinib--a new standard treatment for relapsed mantle cell lymphoma?
Topics: Adenine; Antineoplastic Agents; Female; Humans; Lymphoma, Mantle-Cell; Male; Piperidines; Pyrazoles; | 2016 |
Postibrutinib outcomes in patients with mantle cell lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Disease Progression; Female; | 2016 |
Adverse event potentially due to an interaction between ibrutinib and verapamil: a case report.
Topics: Adenine; Aged; Antihypertensive Agents; Antineoplastic Agents; Cytochrome P-450 CYP3A Inhibitors; Di | 2016 |
The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Cell Line, Tumor; Comb | 2016 |
[Ibrutinib prescription in B-cell lymphoid neoplasms].
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; B-Lymphocytes; Clinical Trials as Topic; Drug Resistan | 2016 |
Targeting protein kinase C in mantle cell lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Cell Death; Drug Resistance, Ne | 2016 |
Ibrutinib-associated tumor lysis syndrome in a patient with mantle cell lymphoma: A case report.
Topics: Adenine; Aged; Antineoplastic Agents; Humans; Lymphoma, Mantle-Cell; Male; Piperidines; Protein Kina | 2017 |
Ibrutinib-related atrial fibrillation in patients with mantle cell lymphoma.
Topics: Adenine; Aged; Aged, 80 and over; Atrial Fibrillation; Female; Follow-Up Studies; Humans; Incidence; | 2016 |
Chemotherapy of mantle cell lymphoma relapsed or refractory chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Agents; Bendamustine Hydrochloride; Bortezomib; Chromosomes, Human, Pair 17; | 2016 |
Ibrutinib is a safe and effective therapy for systemic mantle cell lymphoma with central nervous system involvement - a multi-centre case series from the United Kingdom.
Topics: Adenine; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain; Central | 2017 |
Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations.
Topics: Adenine; CARD Signaling Adaptor Proteins; Drug Resistance, Neoplasm; Genetic Heterogeneity; Guanylat | 2016 |
CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma.
Topics: Adenine; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Cyclin D1; Drug Resistan | 2016 |
HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Amino Acid Substitution; Animals; Cell Line, Tumor; Dr | 2016 |
Mantle Cell Lymphoma with Central Nervous System Involvement Simulating Bilateral Subdural Hematomas.
Topics: Adenine; Aged; Antineoplastic Agents; Brain Neoplasms; Diagnosis, Differential; Hematoma, Subdural; | 2017 |
Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; P | 2017 |
Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; B-Lymphocytes; Cell Li | 2017 |
Staphylococcus aureus meningitis in a patient with mantle cell lymphoma under treatment with ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Agents; Delayed Diagnosis; Diseas | 2017 |
Novel targeted therapies for mantle cell lymphoma.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antigens, CD20; Antigens | 2012 |
The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Apopto | 2013 |